VU Research Portal

Conservative treatment of acute and chronic nonspecific low back pain - A systematic review of randomized controlled trials of the most common interventions

van Tulder, M.W.; Koes, B.W.; Bouter, L.M.

published in

Spine
1997

DOI (link to publisher)

[10.1097/00007632-199709150-00012](https://doi.org/10.1097/00007632-199709150-00012)

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

van Tulder, M. W., Koes, B. W., & Bouter, L. M. (1997). Conservative treatment of acute and chronic nonspecific low back pain - A systematic review of randomized controlled trials of the most common interventions. *Spine*, 22(18), 2128-2156. <https://doi.org/10.1097/00007632-199709150-00012>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Conservative Treatment of Acute and Chronic Nonspecific Low Back Pain

A Systematic Review of Randomized Controlled Trials of the Most Common Interventions

Maurits W. van Tulder, PhD, Bart W. Koes, PhD, and Lex M. Bouter, PhD

Study Design. A systematic review of randomized controlled trials.

Objectives. To assess the effectiveness of the most common conservative types of treatment for patients with acute and chronic nonspecific low back pain.

Summary of Background Data. Many treatment options for acute and chronic low back pain are available, but little is known about the optimal treatment strategy.

Methods. A rating system was used to assess the strength of the evidence, based on the methodologic quality of the randomized controlled trials, the relevance of the outcome measures, and the consistency of the results.

Results. The number of randomized controlled trials identified varied widely with regard to the interventions involved. The scores ranged from 20 to 79 points for acute low back pain and from 19 to 79 points for chronic low back pain on a 100-point scale, indicating the overall poor quality of the trials. Overall, only 28 (35%) randomized controlled trials on acute low back pain and 20 (25%) on chronic low back pain had a methodologic score of 50 or more points, and were considered to be of high quality. Various methodologic flaws were identified. Strong evidence was found for the effectiveness of muscle relaxants and nonsteroidal anti-inflammatory drugs and the ineffectiveness of exercise therapy for acute low back pain; strong evidence also was found for the effectiveness of manipulation, back schools, and exercise therapy for chronic low back pain, especially for short-term effects.

Conclusions. The quality of the design, execution, and reporting of randomized controlled trials should be improved, to establish strong evidence for the effectiveness of the various therapeutic interventions for acute and chronic low back pain. [Key words: conservative treatment, low back pain, methodology, randomized controlled trials, systematic review] **Spine**

1997;22:2128-2156

Low back pain (LBP) causes major medical and economical problems in Western industrialized countries, which is demonstrated by the high direct and indirect costs¹⁵¹ and the large variety of therapeutic interventions available for its treatment.¹⁵² The effectiveness of most of these interventions, however, has not yet been demonstrated beyond doubt. One of the major challenges for researchers in the field of LBP is to provide evidence of which treatment, if any, is the most optimal for (subgroups of) patients with LBP.

In 1987, the Quebec Task Force (QTF) on Spinal Disorders published management guidelines for activity-related spinal disorders on the basis of the strength of the scientific evidence.¹³⁹ The QTF regarded the randomized controlled trial (RCT) to be the strongest scientific proof of the effectiveness of an intervention. However, not only the type of study but also the methodologic quality of the study was assessed in the review process. Approximately 18% of the 469 studies selected by the QTF were RCTs, of which approximately 56% were considered to be of good or very good methodologic quality. According to the QTF, only bed rest for less than 2 days and back school were demonstrated by sound RCTs to be effective in the treatment of acute LBP for subjects not at work. No single therapeutic intervention was demonstrated to be effective in the treatment of chronic LBP. Since the publication of the report of the QTF, several other attempts have been made in the United States and the United Kingdom to incorporate the available scientific evidence about the most optimal LBP treatment strategy into clinical guidelines.^{15,133}

The current interest in evidence-based medicine has led to an extensive increase in the publication of systematic reviews. Recently, several systematic reviews of RCTs on the effectiveness of various therapeutic interventions available for the treatment of LBP, such as bed rest, orthoses, exercise therapy, back schools, and spinal manipulation have been published by our research group.^{78,79,84,85} However, most of these systematic reviews gave a summary of the literature on the effectiveness of one therapeutic intervention only, were based on literature published before 1992, and did not evaluate

From the Institute for Research in Extramural Medicine, Vrije Universiteit, Amsterdam, The Netherlands.

Supported by a grant from the Dutch Health Insurance Board.

Acknowledgment date: May 30, 1996.

First revision date: September 9, 1996.

Second revision date: December 13, 1996.

Acceptance date: December 23, 1996.

Device status category: 1.

the scientific evidence for acute and chronic LBP separately. Therefore, we decided to systematically review the scientific literature, to analyze the effectiveness of the most common conservative treatment options for acute and chronic nonspecific LBP.

Because the RCT is generally accepted as the paradigm of intervention research, we have restricted ourselves to the outcomes of RCTs. Because even RCTs may show biased outcomes, we also assessed the methodologic quality of the RCTs. Previously published reviews^{78,79,84,85} about the effectiveness of bed rest and orthoses, exercise therapy, back schools, and spinal manipulation were updated, and we also included RCTs that evaluated the effectiveness of analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, antidepressants, epidural steroid injections, transcutaneous electrical nerve stimulation (TENS), traction, behavior therapy, orthoses, electromyographic biofeedback, and acupuncture.

Materials and Methods

Selection of Studies. A search was made of the MEDLINE database from 1966 through September 1995, the EMBASE drugs and pharmacology database from 1980 through September 1995, and the PsycLIT database from 1984 through September 1995, using Medical Subject Headings and free text words. The keywords used were: low back pain, backache, musculoskeletal diseases, joint diseases, spinal diseases, and physical therapy, and also the names of specific interventions. Subsequently, the references given in relevant identified publications were further examined. We reviewed the titles and abstracts of the identified articles, to determine the potential relevancy of the articles for our systematic review. If there was any doubt, the article was retrieved and read. Abstracts and unpublished studies were not selected. A study was included if:

- 1) it concerned a true randomized trial; trials with quasi-random procedures such as alternate allocation or allocation based on dates of birth were excluded;
- 2) the treatment regimen included one of the aforementioned therapeutic interventions;
- 3) the results, exclusively or separately, concerned patients with acute or chronic LBP;
- 4) the article was published in English.

Acute LBP was defined as LBP persisting for 6 weeks or less, and chronic LBP as LBP persisting for 12 weeks or more. Studies also were included if they reported on a mix of acute and subacute (6–12 weeks) or a mix of patients with subacute and chronic LBP. Studies were excluded if they reported on cervical back pain or a mix of thoracolumbar and cervical back pain, unless the results for thoracolumbar LBP were presented separately. Studies also were excluded if the study population consisted of postoperative patients.

Methodologic Quality of the Studies. All trials were scored according to the criteria listed in Table 1. The criteria are based on generally accepted principles of intervention research and refer to various aspects of study population, interventions, effect, and data presentation and analysis. The same criteria list

Table 1. Criteria List* for the Methodologic Assessment of Randomized Controlled Trials of Therapeutic Interventions for Low Back Pain

Study population
A Homogeneity
B Comparability of relevant baseline characteristics
C Randomization procedure adequate
D Drop-outs described for each study group separately
E <20% loss to follow-up
<10% loss to follow-up
F >50 subjects in the smallest group
>100 subjects in the smallest group
Interventions
G Interventions standardized and described
H Pragmatic study/control group adequate†
I Cointerventions avoided
J Placebo controlled
Effect
K Patients blinded‡
L Outcome measures relevant
M Blinded outcome assessment
N Follow-up period adequate
Data presentation and analysis
O Intention-to-treat analysis
P Frequencies of most important outcomes presented for each treatment group.
Only trials of drug therapy
Q Compliance measured and satisfactory in all study groups

* The operationalization of the criteria has been published in our previous systematic review.^{42–45}

† Criterion H was defined as “pragmatic study” for RCTs of drug therapies, for which a placebo treatment was feasible; criterion H was defined as “control group adequate” for RCTs of the other therapeutic interventions.

‡ Criterion K was not assessed for trials on the efficacy of bed rest.

was used in our previously published systematic reviews.^{78,79,84,85} Each criterion was weighted, resulting in a maximum score of 100 points for each study. The methodologic quality of the RCTs was assessed by two independent reviewers. Disagreements between the two reviewers were resolved by consensus or by consulting a third researcher, who acted as referee. The assessments resulted in a hierarchical list in which higher scores indicate studies with a higher methodologic quality. We used the original scores of our previously published systematic reviews, which were assessed by several different reviewers.^{78,79,84,85} All additional RCTs were assessed by the same two reviewers (BWK and MWvT).

Outcome of the Studies. We extracted the main results from each study according to what we consider to be the most important outcome measures (*i.e.*, pain intensity, overall improvement, and functional status). We considered a study to be positive if the therapeutic intervention involved was more effective than the reference treatment(s) with regard to at least one of these outcome measures. A study was considered to be negative if there were no differences between the intervention under study and the reference treatment on these outcome measures or if the reference treatment was more effective with regard to at least one of these outcome measures. If the therapeutic intervention under study was more effective on one of the outcome measures, but less effective on another, or if these outcome measures were not assessed in a study, no conclusion was drawn (category “no conclusion” in Tables 2–5).

Table 2. Randomized Controlled Trials on the Effectiveness of Drug Therapy in Acute Low Back Pain in Order of Methodologic Score

Reference	Scores for Methodologic Criteria																	Total Score 100	Conclusion*
	A 2	B 5	C 4	D 3	E 4	F 12	G 10	H 5	I 5	J 5	K 9	L 8	M 8	N 5	O 5	P 5	Q 5		
Analgesics																			
Videman ¹⁵⁴	1	3	—	2	4	—	8	5	—	—	5	7	7	3	—	5	—	50	Negative
Wiesel ¹⁶⁰	2	3	—	3	4	—	6	5	5	—	—	4	—	3	5	5	—	45	Positive
Brown ²³	2	1	—	—	2	—	10	5	5	—	—	7	1	3	—	5	—	41	Negative
Evans ⁴²	1	1	—	—	4	—	10	5	5	—	—	5	1	3	—	—	—	35	Negative
Hackett ⁵⁶	1	2	—	3	4	—	—	5	—	5	5	3	3	3	—	—	—	34	Negative
Nwuga ¹²²	2	4	—	—	—	—	5	5	—	—	—	4	1	3	—	5	—	29	Negative
Nonsteroidal anti-inflammatory drugs (NSAIDs)																			
Hosie ⁶⁸	2	5	—	2	4	12	10	5	5	—	5	8	8	3	5	5	—	79	Negative
Amlie ⁵	2	4	—	2	4	12	10	—	5	5	5	7	7	3	—	5	—	71	Positive
Goldie ⁵³	2	4	4	3	4	—	10	—	5	5	5	5	5	3	5	5	—	65	Negative
Weber ¹⁵⁸	2	3	—	—	4	6	10	—	5	5	5	6	6	3	—	5	5	65	Negative
Bakshi ⁹	2	4	—	2	2	6	10	5	—	—	5	7	7	3	5	5	—	63	Negative
Blazek ¹⁶	2	3	—	3	4	—	10	5	5	—	5	6	6	3	5	5	—	62	Negative
Szpalski ¹⁴⁴	2	4	—	1	4	—	10	—	5	5	5	6	6	3	—	5	—	56	Positive
Lacey ⁸⁷	—	3	—	1	2	12	10	—	—	5	5	6	6	3	—	—	—	53	Positive
subgroup																			
Videman ¹⁵⁴	1	3	—	2	4	—	10	5	—	—	5	7	7	3	—	5	—	52	Negative
Sweetman ¹⁴³	2	4	—	—	2	—	8	5	—	—	5	8	8	3	—	5	—	50	Negative
Orava ¹²⁵	2	5	—	1	4	6	10	5	—	—	—	8	—	3	—	5	—	49	Negative
Wiesel ¹⁶⁰	2	3	—	3	4	—	8	5	5	—	—	4	—	3	5	5	—	47	Negative
Agrifoglio ²	1	3	—	2	2	—	10	5	—	—	5	5	5	3	—	5	—	46	Positive
Weber ¹⁵⁷	2	2	—	—	—	—	10	—	—	5	5	6	6	3	—	5	—	44	Positive
Waterworth ¹⁵⁶	2	2	—	2	4	—	10	5	5	—	—	8	—	3	—	—	—	41	Negative
Brown ²³	2	1	—	—	2	—	10	5	5	—	—	7	1	3	—	5	—	41	Negative
Evans ⁴²	1	1	—	—	4	—	10	5	5	—	—	5	1	3	—	—	—	35	Positive
Aghababian ¹	2	3	—	1	—	—	10	5	—	—	—	6	—	3	—	5	—	35	Positive
Postacchini ¹²⁷	2	—	—	—	2	—	8	5	—	—	—	5	—	5	—	—	—	27	Not clear
Muscle relaxants																			
Berry ¹⁴	1	3	—	3	4	6	8	5	5	5	5	4	4	3	5	5	—	66	Positive
Baratta ¹⁰	—	3	4	—	4	6	8	—	—	5	5	8	8	3	5	5	—	64	Positive
Casale ²⁷	1	4	4	—	4	—	8	—	5	5	5	3	3	3	5	5	—	55	Positive
Boyles ²¹	2	3	4	3	2	—	8	5	5	—	5	7	7	3	—	—	—	54	Positive
Hindle ⁶⁶	—	2	4	3	2	—	8	5	—	5	5	8	8	3	—	—	—	53	Positive
Middleton ¹¹⁴	2	3	—	—	4	6	8	5	5	—	—	7	—	3	5	5	—	53	Negative
Dapas ³⁰	1	3	—	—	—	6	8	—	5	5	5	8	8	3	—	—	—	52	Positive
Rollings ¹³²	2	3	4	3	—	—	8	5	5	—	5	7	7	3	—	—	—	52	Negative
Berry ¹³	1	3	—	3	2	6	8	—	—	5	5	4	4	3	—	5	—	49	Positive
Gold ⁵²	—	1	—	—	4	—	8	5	—	5	5	4	4	3	5	—	—	44	Positive
Sweetman ¹⁴³	1	1	—	3	—	—	8	5	—	—	5	5	5	3	—	5	—	43	Positive
Borenstein ²⁰	1	2	—	—	4	—	8	5	5	—	—	7	—	3	5	—	—	40	Positive
Hingorani ⁶⁷	—	—	—	—	4	—	8	—	—	5	5	2	2	3	5	5	—	39	Negative
Tervo ¹⁴⁵	—	3	4	—	—	—	8	—	—	—	5	2	2	3	—	—	—	27	Positive
Summary																			
	A 2	B 5	C 4	D 3	E 4	F 17	G 10	H 5	I 5	J 5	K 5	L 10	M 10	N 5	O 5	P 5		Total 100	
Epidural steroid injections																			
Mathews ¹⁰⁶	1	3	4	3	4	—	10	—	5	5	3	4	4	5	5	5		61	Positive

* Positive if the therapeutic intervention involved was more effective than the reference treatment(s) with regard to pain intensity, overall improvement, or functional status; negative if there was no difference between the intervention and the reference treatment(s) on these outcome measures or if the reference treatment was more effective.

Levels of Evidence. Our conclusions on the effectiveness of the therapeutic interventions were based on the strength of the scientific evidence. For this purpose, we used a rating system based on the one used in the U.S. Clinical Practice Guideline for Acute Low Back Problems in Adults.¹⁵ The rating system consisted of four levels of scientific evidence based on the quality and the outcome of the studies:

- 1) Strong evidence—multiple relevant, high quality RCTs.
- 2) Moderate evidence—one relevant, high quality RCT and one or more relevant, low quality RCTs.

- 3) Limited evidence—one relevant, high quality RCT or multiple relevant, low quality RCTs.
- 4) No evidence—only one relevant, low quality RCT, no relevant RCTs or contradictory outcomes.

An RCT was regarded as relevant if at least one of the outcome measures concerned pain intensity, overall improvement, or functional status. An RCT was (arbitrarily) considered to be of high quality if the methodologic score was 50 points or more, and of low quality if the methodologic score was less than 50 points.

Table 3. Randomized Controlled Trials on the Effectiveness of Other Conservative Treatments for Acute Low Back Pain in Order of Methodologic Score

Reference	Scores for Methodologic Criteria																Total Score 100	Conclusion*
	A 2	B 5	C 4	D 3	E 4	F 17	G 10	H 5	I 5	J 5		L 10	M 15	N 5	O 5	P 5		
Bed rest																		
Deyo ³³	2	5	4	—	4	17	10	5	5	—		10	6	—	5	—	73	Negative
Gilbert ^{40,49}	2	5	2	—	2	8	10	5	—	5		6	3	5	—	5	58	Negative
Malmivaara ⁹⁹	1	5	4	—	2	8	5	5	—	5		10	3	—	—	5	53	Negative
Wilkinson ¹⁶¹	2	5	2	—	—	—	10	5	5	5		6	—	—	—	5	45	Negative
Postacchini ¹²⁷	2	3	—	—	2	—	5	5	—	—		6	—	5	—	—	28	Negative
Wiesel ¹⁶⁰	2	3	—	—	4	—	—	—	5	—		4	—	—	5	—	23	Positive
	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Total	
	2	5	4	3	4	17	10	5	5	5	5	10	10	5	5	5	100	
Exercise therapy																		
Faas ^{43,44}	2	5	4	—	2	17	10	5	5	5	3	6	—	5	—	5	74	Negative
Evans ^{40,49}	2	5	—	—	—	8	10	5	—	—	—	10	2	5	—	5	52	Negative
Malmivaara ⁹⁹	1	5	4	—	2	8	5	5	—	—	—	10	2	—	—	5	47	Negative
Stankovic ^{140,141}	1	3	4	3	4	—	10	5	—	—	—	2	—	5	5	5	47	Positive
Waterworth ¹⁵⁶	2	5	—	3	4	—	5	5	5	—	—	6	—	3	5	—	43	Negative
Nwuga ¹²¹	2	4	2	—	—	—	10	5	—	—	3	2	2	3	—	5	38	Negative
Farrell ⁴⁵	2	5	—	—	2	—	10	5	—	—	—	8	2	3	—	—	37	Negative
Davies ³¹	2	3	—	—	4	—	—	5	—	—	3	6	2	3	—	5	33	Negative
Delitto ³²	1	2	2	—	—	—	10	5	—	—	—	2	—	3	—	5	30	Positive
Nwuga ¹²³	2	2	2	—	—	—	—	5	—	—	3		2	3	—	5	28	Positive
Back schools																		
Bergquist ¹¹	2	3	2	—	2	8	10	5	—	—	—	4	—	5	—	5	46	Positive
Stankovic ^{140,141}	2	3	4	—	4	—	10	—	—	—	—	6	—	5	5	—	39	Negative
Lindequist ⁹³	1	2	—	—	4	—	5	5	—	—	—	4	—	5	5	5	36	Negative
Morrison ¹¹⁷	—	—	—	—	—	8	—	—	—	—	—	4	—	5	—	5	22	Positive
Manipulation																		
MacDonald ⁹⁸	1	4	—	3	4	—	10	5	5	—	—	6	—	3	5	5	51	Overall negative; positive subgroup only
Sanders ¹³⁵	—	2	2	3	4	—	10	5	5	5	3	2	2	3	5	—	51	Not clinically relevant
Hadler ⁵⁷	1	3	—	—	4	—	10	5	5	—	3	4	—	3	5	5	48	Positive subgroup
Bergquist ¹¹	2	1	2	—	4	8	10	5	—	5	2	2	—	5	—	—	46	Positive vs. placebo; negative vs. back school
Mathews ¹⁰⁷	—	2	—	3	2	17	5	5	—	—	—	2	—	5	—	5	46	Positive subgroup
Helliwell ⁶²	1	3	—	3	4	—	5	5	5	—	—	2	2	3	5	5	43	Negative
Glover ⁵⁰	—	3	4	3	4	—	5	—	5	5	—	2	—	3	5	—	39	Negative
Blomberg ^{17–19}	1	2	4	—	4	—	—	5	—	—	—	6	2	3	5	5	37	Positive
Rasmussen ¹²⁸	1	1	—	—	4	—	—	5	5	—	—	4	—	3	5	5	33	Positive
Delitto ³²	—	1	2	—	4	—	10	5	—	—	—	2	—	3	—	5	32	Positive
Farrell ⁴⁵	2	4	—	—	2	—	—	5	5	—	—	6	—	3	—	5	32	Positive
Nwuga ¹²¹	2	3	—	—	—	—	10	5	5	—	—	2	2	3	—	—	32	Positive
Waterworth ¹⁵⁶	2	3	—	3	4	—	—	5	5	—	—	6	—	3	—	—	31	Negative
Postacchini ¹²⁷	—	2	—	—	2	—	—	5	5	5	—	4	—	5	—	—	28	Positive
Wreje ¹⁶³	1	2	—	—	2	—	10	—	—	5	—	2	—	3	—	—	25	Positive
Godfrey ⁵¹	1	1	—	—	2	—	—	5	—	—	—	8	2	3	—	—	22	Negative
Transcutaneous electrical nerve stimulation (TENS)																		
Herman ⁶³	1	3	4	3	—	—	10	—	5	5	3	6	6	5	—	5	56	Negative
Hackett ⁵⁶	1	2	—	3	4	—	—	5	—	5	3	4	4	3	5	—	39	Positive
Traction																		
Larsson ⁸⁹	2	4	—	3	4	—	10	5	—	—	—	2	—	3	5	5	43	Positive
Mathews ¹⁰⁵	—	2	—	3	2	8	5	5	—	—	—	2	—	3	—	5	35	Positive subgroup
Behavior therapy																		
Fordyce ⁴⁶	2	4	—	—	—	—	—	5	—	—	—	4	—	5	—	—	20	Positive

* Positive if the therapeutic intervention involved was more effective than the reference treatment(s) with regard to pain intensity, overall improvement, or functional status; negative if there was no difference between the intervention and the reference treatment(s) on these outcome measures or if the reference treatment was more effective.

■ Results

Methodologic Quality of the Studies

A total of 150 articles met our inclusion criteria, 68 that evaluated treatment of acute LBP, 81 chronic LBP, and 1

acute and chronic LBP. The number of RCTs identified varied widely with regard to the interventions involved (Tables 2–5). Overall, only 28 RCTs (34.6%) that studied acute LBP and 20 RCTs (25%) that studied chronic LBP had a methodologic score of 50 points or more and

Table 4. Randomized Controlled Trials on the Effectiveness of Drug Therapy in Chronic Low Back Pain in Order of Methodologic Score

Reference	Scores for Methodologic Criteria																	Total Score	Conclusion*
	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q		
	2	5	4	3	4	12	10	5	5	5	9	8	8	5	5	5	5	100	
Analgesics																			
Hickey ⁶⁵	2	1	4	2	4	—	10	5	5	—	5	8	8	3	—	5	—	62	Negative
Muscle relaxants																			
Arbus ⁶	1	—	—	3	2	—	10	—	—	5	5	6	6	3	—	5	5	51	Positive
Antidepressants																			
Goodkin ⁵⁴	1	4	—	3	4	—	10	—	—	5	7	6	6	3	5	5	5	64	Negative
Alcoff ³	—	4	—	3	2	—	10	—	—	5	5	6	6	3	5	—	—	49	Positive
Jenkins ⁷¹	1	2	—	—	—	—	10	—	—	5	5	5	5	3	—	—	—	36	Negative
Pheasant ¹²⁶	1	—	—	—	—	—	10	—	—	5	5	3	3	3	—	5	—	35	No conclusion
NSAIDs																			
Hickey ⁶⁵	2	1	4	2	4	—	10	5	5	—	5	8	8	3	—	5	—	62	Positive
Siegmeth ¹³⁸	—	—	—	2	4	—	10	5	5	—	—	8	8	3	—	5	—	50	No conclusion
Videman ¹⁵³	1	3	—	2	4	—	10	5	—	—	5	6	6	—	5	—	—	50	Positive
Berry ¹²	2	—	—	2	4	—	10	5	5	5	5	4	4	3	—	—	—	49	Positive
Matsumo ¹⁰⁸	1	—	—	—	4	6	8	5	5	—	5	3	1	3	—	5	—	46	Negative
Postacchini ¹²⁷	2	—	—	—	2	—	8	5	—	—	—	5	—	5	—	—	—	27	No conclusion
	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P			
	2	5	4	3	4	17	10	5	5	5	5	10	10	5	5	5			
Epidural steroid injections																			
Breivik ²²	1	2	4	3	4	—	10	—	5	5	3	6	6	—	5	5		59	Positive
Bush ²⁵	2	3	—	3	2	—	10	—	—	5	3	6	6	5	5	5		55	Positive
Cuckler ²⁹	2	4	4	3	4	—	10	—	—	5	3	2	2	5	5	5		54	Negative
Serrao ¹³⁷	2	4	—	3	4	—	10	—	—	—	3	6	6	3	5	5		51	Negative
Rocco ¹³¹	1	3	4	—	4	—	10	—	—	—	3	4	4	5	—	5		43	Negative
Ridley ¹²⁹	2	4	2	—	2	—	10	—	—	5	3	4	4	5	—	—		41	Positive short-term only

* Positive if the therapeutic intervention involved was more effective than the reference treatment(s) with regard to pain intensity, overall improvement, or functional status; negative if there was no difference between the intervention and the reference treatment(s) on these outcome measures or if the reference treatment was more effective.

were considered to be of high quality, indicating the overall poor quality of the RCTs. The methodologic scores ranged from 20 to 79 points for acute LBP and 19 to 79 points for chronic LBP. In general, the methodologic quality of the drug therapy trials was somewhat higher than the methodologic quality of the RCTs that studied the other conservative types of treatment. Tables 2 and 4 show the methodologic quality of the RCTs concerning various drug therapies for acute and chronic LBP, respectively. Twenty (50%) of the 40 RCTs that studied drug therapy for acute LBP scored 50 points or more; the median score was 50, with a range of 27 to 79. Ten (56%) of the 18 RCTs that studied drug therapy for chronic LBP scored 50 points or more; the median score was 50, with a range of 27 to 64. Tables 3 and 5 show the methodologic quality of the RCTs that studied the other types of treatment for acute and chronic LBP, respectively. Eight (19.5%) of the 41 RCTs that studied acute LBP scored 50 points or more, the median score being 38.5 and the range 20 to 74. Ten (16%) of the 62 RCTs that studied chronic LBP scored 50 points or more, the median score being 37 and the range 19 to 79.

Effectiveness of the Therapeutic Interventions for Acute Low Back Pain

Analgesics. Six RCTs were identified, of which only one was considered to be of high methodologic quali-

ty.¹⁵⁴ There is moderate evidence (level 2) that analgesics are not more effective than NSAIDs, and no evidence that analgesics are more effective than electroacupuncture or ultrasound for acute LBP (level 4).

Nonsteroidal Anti-Inflammatory Drugs. Nineteen RCTs were identified, of which ten were considered to be of high quality^{5,9,16,53,68,87,143,144,154,158} and nine of low quality.^{1,2,23,42,125,127,156,157,160} Five of the ten high quality RCTs compared NSAIDs with a placebo. Three of these RCTs reported a positive outcome for uncomplicated LBP,^{5,87,144} but only for one of the follow-up moments or for a subgroup only. The two negative high quality RCTs^{53,158} compared NSAIDs with a placebo for patients with acute LBP with sciatica or acute sciatica with nerve root symptoms. The high quality RCT¹⁵⁴ comparing an NSAID to an analgesic did not show a difference in improvement of pain intensity. The three high quality RCTs comparing different types of NSAIDs^{9,16,68} also did not report any differences. There is strong evidence (level 1) that NSAIDs are more effective than a placebo in patients with uncomplicated acute LBP, but not in patients with acute sciatica. There is strong evidence (level 1) that NSAIDs are not more effective than analgesics, and that the various types of NSAIDs, piroxicam, ibuprofen, diclofenac, felbinac, and biarison, are equally effective for acute LBP.

Table 5. Randomized Controlled Trials on the Effectiveness of Other Conservative Treatments in Chronic Low Back Pain in Order of Methodologic Score

Reference	Scores for Methodologic Criteria																Total Score 100	Conclusion*
	A 2	B 5	C 4	D 3	E 4	F 17	G 10	H 5	I 5	J 5	K 5	L 10	M 10	N 5	O 5	P 5		
Manipulation																		
Koes ⁸⁰⁻⁸³	1	3	4	3	—	8	—	5	—	5	3	8	4	3	5	5	57	Positive
Ongley ¹²⁴	2	4	2	—	4	—	5	5	—	—	5	4	4	5	5	5	50	Positive
Triano ¹⁴⁶	1	1	4	—	—	8	5	5	—	5	2	4	—	3	—	5	43	Positive
Gibson ⁴⁸	2	3	—	3	4	—	—	5	5	5	—	4	2	3	—	5	41	Negative
Herzog ⁶⁴	—	1	—	—	—	—	10	5	5	—	—	6	2	3	—	5	37	No conclusion
Evans ⁴¹	—	—	2	—	2	—	5	5	5	—	—	6	2	3	—	5	35	Positive
Waagen ¹⁵⁵	1	2	—	—	—	—	5	5	5	—	5	4	2	3	—	—	32	Positive
Arkuszewski ⁷	—	1	2	—	4	—	—	5	—	—	—	4	—	5	5	5	31	Positive
Postacchini ¹²⁷	1	3	—	—	2	—	5	5	—	—	—	6	—	5	—	—	27	Negative
Back schools																		
Harkapaa ^{59,60,110,111}	1	3	—	—	4	17	10	5	—	5	—	10	—	5	5	5	70	Positive
Hurri ^{69,70,73}	2	3	—	—	4	8	10	5	—	—	—	8	—	5	5	5	55	Positive
Linton ⁹⁶	1	1	—	3	4	—	10	5	—	—	—	6	—	5	5	5	45	Positive
Lankhorst ⁸⁸	2	3	2	—	2	—	5	5	—	—	3	6	—	5	—	5	38	Negative
Keijzers ⁷⁵	1	—	—	3	2	—	—	5	—	—	—	8	—	5	—	5	29	Negative
Donchin ³⁷	—	3	—	—	—	—	5	5	—	—	—	4	—	5	5	—	27	Negative
Postacchini ¹²⁷	1	3	—	—	2	—	5	5	—	—	—	6	—	5	—	—	27	Positive
Herzog ⁶⁴	1	1	—	—	—	—	—	5	—	—	—	6	2	3	—	5	23	No conclusion
Klaber ⁷⁷	1	3	—	—	2	—	5	5	—	—	—	4	—	3	—	—	23	Positive
Keijzers ⁷⁴	1	1	—	—	—	—	5	5	—	—	—	4	—	3	—	—	19	No conclusion
EMG biofeedback																		
Asfour ⁸	1	3	—	—	4	—	10	5	—	—	—	4	—	3	5	5	40	Negative
Bush ²⁴	1	4	—	—	4	—	10	—	—	5	3	4	—	3	5	—	39	Negative
Nouwen ¹²⁰	1	2	—	3	4	—	10	—	—	—	—	2	—	3	5	5	35	Negative
Stuckey ¹⁴²	1	—	—	—	—	—	—	5	—	5	3	4	4	3	—	5	30	Negative
Donaldson ³⁶	1	—	—	—	—	—	5	5	—	—	—	4	—	3	—	5	23	Positive
Exercise therapy																		
Deyo ³⁴	1	3	4	3	2	8	10	5	—	—	—	10	2	3	5	5	61	Positive
Hansen ⁵⁸	1	4	2	3	—	8	10	5	—	5	3	4	4	5	—	5	59	Positive
Manniche ^{100,101}	2	1	4	3	2	—	10	5	—	—	—	10	2	5	5	5	54	Positive
Elnaggar ³⁹	1	3	2	3	4	—	10	5	—	—	—	4	2	3	5	5	47	Negative
Lidström ⁹²	1	2	—	3	4	—	10	5	—	—	—	6	2	3	5	5	46	Positive
Manniche ¹⁰²	1	3	2	3	—	—	10	5	—	—	—	8	2	5	—	5	44	Negative
Lindström ^{94,95}	2	2	—	—	4	8	5	5	—	—	—	4	—	2	5	5	42	Positive
Johanssen ⁷²	1	2	—	3	—	—	10	5	—	—	—	10	—	5	—	5	41	Negative
Turner ¹⁴⁹	1	1	—	—	—	—	10	5	—	—	—	8	2	5	—	5	37	Negative
Kendall ⁷⁶	1	—	2	—	2	—	10	5	—	—	—	6	2	3	—	5	36	Positive
Risch ¹³⁰	—	3	2	—	4	—	5	5	—	—	—	4	—	3	5	5	36	Positive
Martin ¹⁰⁴	2	—	2	—	—	—	10	5	—	5	—	6	2	3	—	—	35	Negative
Buswell ²⁶	—	1	—	—	—	—	10	5	—	—	—	4	—	5	5	—	30	Negative
Sachs ¹³⁴	—	1	—	—	4	—	10	5	—	—	—	2	—	3	5	—	30	Negative
Frost ⁴⁷	2	4	2	—	—	—	—	5	—	—	—	6	—	5	—	5	29	Positive
White ¹⁵⁹	1	—	—	—	—	8	—	5	5	—	—	2	—	3	—	—	24	Negative
Traction																		
Heijden ⁶¹	1	2	4	—	2	—	10	—	—	5	5	6	6	5	5	5	56	Positive
Orthoses																		
Million ¹¹⁵	2	2	—	—	—	—	10	5	—	—	3	8	—	3	—	—	38	Positive
Behavior therapy																		
Lindström ^{94,95}	2	2	—	—	4	8	5	5	—	—	—	4	—	5	5	5	45	Positive
Turner ¹⁴⁸	1	1	—	—	4	—	10	5	—	—	—	8	—	5	5	5	44	Positive
Nicholas ¹¹⁹	1	1	—	—	2	—	10	5	5	—	—	6	—	5	—	5	40	Positive
Nicholas ¹¹⁸	1	1	—	—	—	—	10	5	5	—	—	6	—	5	—	5	38	Positive
Turner ¹⁴⁷	—	2	—	—	—	—	10	5	—	—	—	10	—	5	—	5	37	Positive
Turner ¹⁴⁹	1	1	—	—	—	—	10	5	—	—	—	8	2	5	—	5	37	Positive
Turner ¹⁵⁰	1	1	—	—	—	—	10	5	—	—	—	8	2	5	—	5	37	Positive
Altmaier ⁴	1	2	—	—	2	—	10	5	—	—	—	6	—	5	—	5	36	Negative
Stuckey ¹⁴²	1	—	—	—	—	—	10	5	—	—	3	4	—	3	—	5	31	Positive
McCauley ¹⁰⁹	1	3	—	—	—	—	10	5	—	—	—	6	—	3	—	—	28	Negative
Donaldson ³⁶	1	—	—	—	—	—	5	5	—	—	—	4	—	5	—	5	25	Negative
Transcutaneous electrical nerve stimulation (TENS)																		
Deyo ³⁴	1	3	4	3	2	8	10	—	5	5	5	10	10	3	5	5	79	Negative
Marchand ¹⁰³	1	3	—	—	4	—	10	5	—	5	5	2	2	5	5	5	52	Positive short-term
Lehmann ^{90,91}	1	—	—	—	—	—	10	5	—	5	3	4	4	3	—	5	35	Negative
Acupuncture																		
Coan ²⁸	1	3	4	—	4	—	5	5	—	—	—	8	—	5	5	5	56	Positive
Mendelson ^{112,113}	1	3	—	—	—	—	10	—	—	5	3	6	6	3	—	5	42	Negative
MacDonald ⁹⁷	—	—	—	—	4	—	10	—	—	5	3	6	6	3	5	—	42	Positive
Edelist ³⁸	—	—	—	—	4	—	10	—	—	5	3	2	2	3	5	5	39	Negative
Lehmann ^{90,91}	1	—	—	—	—	—	10	5	—	5	3	4	4	3	—	—	35	Positive
Gunn ⁵⁵	1	2	2	—	—	—	5	5	—	—	—	2	—	5	—	5	27	Positive

* Positive if the therapeutic intervention involved was more effective than the reference treatment(s) with regard to pain intensity, overall improvement, or functional status; negative if there was no difference between the intervention and the reference treatment(s) on these outcome measures or if the reference treatment was more effective.

Muscle Relaxants. Eight high quality RCTs^{10,14,21,27,30,66,114,132} and six low quality RCTs^{13,20,52,67,143,145} were identified that studied the effectiveness of muscle relaxants. All five high quality RCTs comparing a muscle relaxant with a placebo^{10,14,27,30,66} reported a better improvement in pain intensity for the muscle relaxant. The three high quality RCTs comparing different types of muscle relaxants^{21,114,132} reported no differences with regard to pain intensity. There is strong evidence (level 1) that muscle relaxants are more effective than a placebo for acute LBP. There is also strong evidence (level 1) that different types of muscle relaxants are equally effective for acute LBP.

Epidural Steroid Injections. Only one high quality RCT¹⁰⁶ was identified, indicating that there is limited evidence on the effectiveness of epidural steroid injections for acute LBP with nerve root pain and radicular neurologic deficit (level 3).

Bed Rest. Six RCTs were identified, three of high quality^{33,40,49,99} and three of low quality.^{127,160,161} Five of the trials, including the three high quality RCTs, reported negative results. There is strong evidence (level 1) that bed rest is not an effective treatment option for acute LBP.

Exercise Therapy. Ten RCTs were identified, two high quality^{40,43,44} and eight low quality RCTs.^{31,32,45,99,121,123,140,141,156} Seven RCTs,^{31,40,43-45,99,121,156} including the two of high quality, reported negative results, and three RCTs reported positive results.^{32,123,140,141} There is strong evidence that exercise therapy is not more effective than other conservative treatments, including no intervention, for acute LBP (level 1).

Back Schools. Four low quality RCTs^{11,93,117,140,141} were identified on the effectiveness of some type of back school. There is no evidence (level 4) that a back school is effective for acute LBP, because of the contradictory results.

Manipulation. Sixteen RCTs were identified, of which only two were of high quality^{98,135} and 14 of low quality.^{11,17,18,19,32,45,50,51,57,62,107,121,127,128,156,163} Twelve trials, including the two high quality RCTs, reported positive results, and four trials^{50,51,62,156} reported negative results. However, in one of the high quality trials,¹³⁵ a fatal flaw (a follow-up period of only 30 minutes after one single manipulation) was identified, and this trial was not included in our assessment of evidence. In four nonpragmatic trials, manipulation was compared with some type of placebo therapy.^{11,50,127,163} Three of the four low quality RCTs^{11,127,163} reported a positive result for manipulation compared with placebo. Fourteen pragmatic trials (one high quality RCT) were identified that compared manipulation with other conservative types of treatment.^{11,17-19,32,45,51,57,62,98,121,127,128,135,156} In 10 of these RCTs, the results were positive, and in 4 RCTs,^{51,62,98,156} including one high quality RCT,⁹⁸

the results were negative. There is limited evidence that manipulation is more effective than a placebo treatment for acute LBP (level 3). There is no evidence that manipulation is more effective than (other) physiotherapeutic applications (massage, shortwave diathermy, exercises) or drug therapy (analgesics, NSAIDs) for acute LBP, because of the contradictory results.

Transcutaneous Electrical Nerve Stimulation. Two trials studied the effectiveness of TENS, of which one was of high⁶³ and one of low quality.⁵⁶ There is no evidence (level 4) that TENS is an effective treatment for acute LBP, because of the contradictory results.

Traction. Only two low quality RCTs^{89,105} were identified, which both reported a positive result. There is limited evidence (level 3) that traction is effective for acute LBP.

Behavior Therapy. Only one low quality RCT⁴⁶ was identified, indicating that there is no evidence (level 4) on the effectiveness of behavior therapy for acute LBP.

Effectiveness of the Therapeutic Interventions for Chronic Low Back Pain

Analgesics. Only one high quality RCT⁶⁵ was identified on the effectiveness of analgesics for chronic LBP, indicating that there is limited evidence that paracetamol is equally effective as diflunisal (NSAID) (level 3).

Muscle Relaxants. Because only one high quality RCT⁶ was identified, there is limited evidence for the effectiveness of muscle relaxants for chronic LBP (level 3). This RCT reported a positive result of tetrazepam compared with a placebo.

Antidepressants. One high quality⁵⁴ and three low quality RCTs^{3,71,126} were identified. All four RCTs compared an antidepressant with a placebo.^{3,54,71,126} There is moderate evidence that antidepressants are not effective for chronic LBP (level 2).

Nonsteroidal Anti-Inflammatory Drugs. Six RCTs were identified, three high quality RCTs^{65,138,153} and three low quality RCTs.^{12,108,127} One low quality RCT compared two types of NSAIDs with a placebo in a cross-over design and had a positive outcome.¹² Of the two pragmatic RCTs that compared NSAIDs with other conservative types of treatment, the high quality RCT reported a positive outcome, with overall improvement.^{65,127} The results of the four RCTs that compared two different types of NSAIDs, two high quality and two low quality, were all negative.^{12,108,138,153} There is moderate evidence (level 2) that NSAIDs are effective for chronic LBP, and there is strong evidence (level 1) that the various types of NSAIDs, piroxicam, indomethacin, ibuprofen, diclofenac, ketoprofen, naproxen, and diflunisal, are equally effective.

Epidural Steroid Injections. Four high quality^{22,25,29,137} and two low quality RCTs^{129,131} that studied epidural steroid injections were identified. Two of the six trials compared the epidural steroid injection with a placebo injection (saline).^{22,129} Both trials, one high quality and one low quality, reported significantly better short-term results of pain relief from epidural steroid injection. Epidural steroid injection was also compared with an injection of bupivacaine,²² procaine,²⁹ midazolam,¹³⁷ or lignocaine and morphine.¹³¹ Three of these four trials were of high quality and one of low quality. There is moderate evidence that epidural steroid injections are more effective than a placebo in the short-term for chronic LBP (level 2). However, there is no evidence that epidural steroid injections are more effective than injections of a local anesthetic or a muscle relaxant for chronic LBP (level 4), because the results of these trials were contradictory.

Manipulation. Two high quality^{80-83,124} and seven low quality RCTs^{7,41,48,64,127,146,155} were identified. Six trials, including the two high quality RCTs, reported positive results, two trials reported negative results, and, in one trial, no clear conclusion was drawn (we considered this trial to be negative). In five nonpragmatic trials, manipulation was compared with a placebo therapy.^{48,80-83,124,127,146} The two high quality RCTs reported a positive result for manipulation compared with a placebo.^{80-83,124} Eight pragmatic trials (one high quality RCT) were identified that compared manipulation with other conservative types of treatment.^{7,41,48,64,80-83,127,146,155} In five of these RCTs, including one high quality RCT, the results were positive, and in three RCTs, the results were negative. There is strong evidence that manipulation is more effective than a placebo treatment for chronic LBP (level 1). There is moderate evidence that manipulation is more effective for chronic LBP than usual care by the general practitioner, bed-rest, analgesics, and massage (level 2).

Back Schools. Ten RCTs, two of high quality^{59,60,69,70,73,110,111} and eight of low quality,^{37,64,74,75,77,88,96,127} were identified that studied the effectiveness of some type of back school. In two studies, no clear conclusion was drawn, but we considered one of these trials as positive⁶⁴ and one as negative.⁷⁴ In seven nonpragmatic trials, a back school was compared with no treatment, a waiting-list control group, and a placebo treatment.^{37,59,60,69,70,73-75,88,96,110,111} The two nonpragmatic high quality RCTs reported positive outcomes of an intensive modified Swedish back school program compared with no actual treatment in an occupational setting.^{59,60,69,70,73,110,111} Of the four pragmatic low quality trials, three reported positive^{64,77,127} and one reported negative³⁷ results. There is strong evidence (level 1) that an intensive back school program in an occupational setting is more effective than no actual treatment for chronic LBP. There is limited evidence

(level 3) that a back school is more effective than other conservative types of treatment for chronic LBP.

Electromyographic Biofeedback. Five low quality trials were identified that studied the effectiveness of electromyographic biofeedback.^{8,24,36,120,142} The sample sizes of all study groups were very small, not exceeding 22 patients. Four RCTs reported negative results^{8,24,120,142} and only one RCT reported a positive result.³⁶ There is limited evidence that electromyographic biofeedback is not effective for chronic LBP (level 3).

Exercise Therapy. Sixteen trials were identified, three high quality^{34,58,100,101} and 13 low quality^{26,39,47,72,76,92,94,95,102,104,130,134,149,159} RCTs. The number of RCTs that reported positive and negative results was equal ($n = 8$), but the three high quality RCTs all reported positive results. In nine trials, exercises were compared with various reference treatments, such as traditional care, physical therapy, hot packs and rest, behavioral therapy, no exercise, a waiting-list control group, or a placebo treatment.^{34,47,58,92,94,95,104,130,134,149} Six of these nine trials, including two high quality RCTs, reported a positive result, whereas three low quality RCTs reported a negative result. The effectiveness of different types of exercises was examined in nine trials.^{26,39,72,76,92,100-102,104,159} Six low quality trials reported a negative result and one high quality and two low quality trials reported a positive result. There is strong evidence that exercise therapy is effective for chronic LBP (level 1), and there is no evidence in favor of one of the exercises due to the contradictory results (level 4).

Traction. Only one high quality RCT⁶¹ was identified that studied the effectiveness of traction in the treatment of chronic LBP.⁶¹ Although the authors' conclusion was positive, no significant differences were found with regard to pain intensity and functional status. There is limited evidence that traction is not effective for chronic LBP (level 3).

Orthoses. Only one low quality RCT¹¹⁵ was identified, indicating that there is no evidence (level 4) for the effectiveness of orthoses in the treatment of chronic LBP.

Behavior Therapy. Eleven low quality RCTs were identified that studied the effectiveness of behavior therapy for chronic LBP.^{4,36,94,95,109,118,119,142,143,147-150,151} Eight of the 11 trials reported positive results for behavior therapy, and three trials reported negative results. The four trials by Turner et al^{147-150,151} reported positive results of various kinds of behavior therapies compared with a waiting-list control group. In eight trials, behavior therapy was compared with other conservative types of treatment.^{4,36,94,95,109,118,119,142,147} Five of these trials had positive results, and three had negative results. Five RCTs compared different types of behavior therapies (*i.e.*, operant conditioning, cognitive treatment [coping strategies], and progressive muscle relax-

ation).^{118,147,148,150,151} Three trials reported negative results and two reported positive results for this comparison. There is limited evidence that behavior therapy is an effective treatment modality for chronic LBP with good short-term results (level 3). There is no evidence that one particular behavior therapy is more effective than the other behavior therapies (level 4), because the results of these trials were contradictory.

Transcutaneous Electrical Nerve Stimulation. Three trials studied the effectiveness of TENS compared with TENS for chronic LBP.^{34,90,91,103} There is no evidence that TENS is an effective treatment for chronic LBP (level 4), because of the contradictory results of the two high quality studies.

Acupuncture. The six trials we identified that studied the effectiveness of acupuncture for chronic LBP were all of low quality.^{28,38,55,90,91,97,112,113} Of the four non-pragmatic trials that used placebo acupuncture or a waiting-list control group as reference treatment, two reported a positive result^{28,97} and two a negative result.^{38,112,113} In the other two pragmatic trials, acupuncture was compared with TENS and placebo TENS,^{90,91} or a standard therapy regimen with acupuncture (dry needling) was compared with a standard therapy regimen alone.⁵⁵ These two trials reported positive results. Because of the contradictory results, there is no evidence (level 4) that acupuncture is an effective treatment for chronic LBP.

■ Discussion

Limitations of Our Systematic Review

We have put much effort into identifying the relevant RCTs that studied the effectiveness of common conservative treatments for acute and chronic LBP. However, a potential limitation of our review might be the literature search, which for several reasons may have introduced a bias. First, some relevant trials might have been missed because they used other keywords or had unclear abstracts. Second, not all published trials are indexed in databases, and we could have missed some relevant trials published in nonindexed journals. Third, we did not make any effort to identify unpublished trials that, in general, are more likely to have negative results. Fourth, we only included trials published in journals in the English language, excluding potentially relevant trials published in other languages. The identification of all relevant trials is crucial to the validity of a systematic review. Therefore, adequate indexing and registration of published trials and trials currently being conducted should be aimed for, to reduce the possibility of bias.³⁵

The choice of the weights that we assigned to the methodologic criteria, obviously, remains arbitrary. The weighting system we used might have influenced the hierarchical order of the trials included in this review. In our previously published review of back schools,⁸⁴ we performed a sensitivity analysis by applying three differ-

ent weighting systems, to evaluate the robustness of the quality assessment. This sensitivity analysis showed more or less the same hierarchical order irrespective of the weighting system used. However, the weighting of methodologic criteria is still under debate.¹¹⁶ In addition, we did not blind the two independent reviewers, with respect to the source and outcome of the trials. The methodologic criteria we used were quite strict and easy to apply, and we presented our quality assessment in a reproducible manner. However, readers may wish to assign their own weights, including equal weights, and reassess the quality of the trials themselves.

Another limitation of our review might be that the scores for each criterion were combined into a single methodologic score. Assessment of the methodologic quality using a total score suggests that methodologic flaws can be compensated, which is probably not the case. Especially "fatal flaws," such as irrelevant outcome measures, high dropout rates (> 50%), or clinically irrelevant follow-up time (e.g., 30 minutes), can influence the internal validity dramatically in otherwise reasonably well performed trials. An example of this was the study of Sanders et al,¹³⁵ which was of methodologic high quality (51 points) but showed a fatal mistake. We did not include this study in our decision-making.

Because we started this review by updating our previously published systematic reviews, we retained the same criteria list.^{78,79,84,85} This criteria list, like many other methodologic quality assessment scales,¹¹⁶ contains items that reflect the internal and external validity and also the precision and quality of the report. Quality assessment scales are still based mainly on general principles of intervention research and not on empirical research.¹¹⁶ Only recently, Schulz et al¹³⁶ provided some empirical evidence that the lack of double-blinding and the inadequacy of allocation concealment are, indeed, associated with bias. Providing empirical evidence of bias for specific methodologic criteria would help to improve quality assessment.

In addition, a limitation of our systematic review might also be that no subgroup analyses could be performed for LBP with and without radiation. Although there may be differences in response to treatment between patients with LBP with and without radiation, many studies report on a mix of patients with LBP with various clinical conditions. Only 37% of the RCTs included in our review reported on a homogeneous study population (Item A). Future RCTs should either evaluate the effectiveness of therapeutic interventions for a clearly defined homogeneous population of patients with LBP or analyze the effectiveness for patients with LBP with and without radiation separately. As in our previously published reviews,^{78,79,84,85} we refrained from statistical pooling because of the generally low methodologic quality of the trials and the heterogeneity of the study populations, outcome measures, follow-up time, and reference treatments. However, the methods of statistical

pooling are rapidly being developed further, and we will attempt to quantitatively pool the results of RCTs on LBP in the near future. In this systematic review, we restricted ourselves to qualitative pooling of the available RCTs by using a system for rating the strength of the evidence that included the quality of the trials, the relative value of the various outcome measures, and the consistency of the outcomes of the trials.¹⁵ However, no consensus has been reached yet on the assessment of the strength of the evidence, and further development of the methods of evidence-based medicine is clearly needed.¹⁶²

■ Methodologic Quality of the Studies

In general, the methodologic quality of the RCTs that studied various therapeutic interventions for acute and chronic LBP appeared to be low. The RCTs that studied drug therapies were, on average, of a higher methodologic quality than the RCTs on other conservative types of treatment. This finding was not very surprising, because the use of a placebo control group and, consequently, the blinding of the patient and the effect measurement is clearly more feasible in drug trials than in trials that evaluate, for example, exercise therapy. We previously discussed the implications of the most common methodologic flaws that occur in RCTs on the effectiveness of treatment for LBP.⁸⁶ Except for the size of the study population, which has implications on the power and the external validity, all these methodologic flaws may have implications on the internal validity of the studies and could consequently result in biased outcomes.

■ Effectiveness of the Therapeutic Interventions

In this review, we assessed the effectiveness of the various interventions for the treatment of acute and chronic LBP, using a rating system for the strength of the scientific evidence. Some problems occurred in assessing the effectiveness of the various conservative treatment options for LBP. A wide variety of reference treatments are used and the outcome of the trials may depend on the effectiveness of the reference treatments. Also, co-interventions are often not prevented or registered, which may indicate that the contrast is not purely the isolated contrast between the index and reference treatments. In addition, different outcome measures were used to evaluate the improvement of the patients, and the same outcome measures may be assessed by different instruments.

Strong evidence was found for the effectiveness of muscle relaxants for acute LBP and for the effectiveness of NSAIDs for uncomplicated acute LBP. Strong evidence also was found against the use of exercise therapy in the treatment of acute LBP. In contrast to the QTF,¹³⁹ we did not conclude that there was any evidence in favor of bed rest or back school for the treatment of acute low back pain. The guidelines of the U.S. Agency for Health Care Policy and Research¹⁵ and the guidelines of the Clinical Standards Advisory Group (CSAG) on Back

Pain in the United Kingdom¹³³ recommended the use of acetaminophen, NSAIDs, muscle relaxants, manipulation, and an active exercise approach as acceptable treatment options for acute LBP.

Regarding the treatment of chronic LBP, strong evidence was found for the effectiveness of manipulation, back schools (in an occupational setting), and exercise therapy, especially with regard to short-term effects. Our results regarding chronic LBP are, to a certain extent, in agreement with the guidelines issued by the QTF¹³⁹ and the CSAG,¹³³ which both suggest the importance of multidisciplinary treatment programs, including exercises and a behavioral approach. However, we only found limited evidence for the effectiveness of behavior therapy. Although the results were quite consistent, all RCTs were of low methodologic quality. According to the QTF and CSAG guidelines,^{133,139} the major goal in the treatment of chronic LBP is return to work or usual activities, and additional therapeutic options for symptomatic pain relief may facilitate this process. The available evidence suggests that NSAIDs might be effective for this purpose, but not physical modalities such as TENS, electromyographic biofeedback, acupuncture, and orthoses.

The inconsistencies between the results of our systematic review and the recommendations for acute LBP of the guidelines from the U.S. Agency for Health Care Policy and Research,¹⁵ the U.K. (CSAG),¹³³ and Canada (QTF)¹³⁹ may partially be explained by cultural differences in interpretation of the available evidence.¹⁶² For example, if there is moderate or limited evidence that an intervention is effective, this intervention might be advised in a country where the intervention is not frequently used. This might especially be the case if there are no or few alternatives. However, in a country where the intervention has been used frequently, the lack of strong evidence may lead to the advice to lower its use. The inconsistencies may also partially be explained by the use of a more recent update of the literature.

■ Conclusions

Many therapeutic interventions are available for and used in the treatment of acute and chronic LBP. We believe that the quality of the design, execution, and reporting of RCTs should, and indeed can, be improved, to establish strong evidence for the effectiveness of the various therapeutic interventions for acute and chronic LBP.

References

1. Aghababian RV, Volturo GA, Heifetz IN. Comparison of Diflunisal and Naproxen in the management of acute low back strain. *Clin Ther* 1986;9(suppl c):47-51.
2. Agrifoglio E, Benvenuti M, Gatto P, et al. Aceclofenac: A new NSAID in the treatment of acute lumbago. Multicentre single blind study vs diclofenac. *Acta Therapeutica* 1994;20:33-43.
3. Alcock J, Jones E, Rust P, Newman R. Controlled trial of

- imipramine for chronic low back pain. *J Fam Pract* 1982;14:841-6.
4. Altmaier EM, Lehmann TR, Russell DW, Weinstein JN, Feng Kao C. The effectiveness of psychological interventions for the rehabilitation of low back pain: A randomized controlled trial evaluation. *Pain* 1992;49:329-35.
5. Amlie E, Weber H, Holme I. Treatment of acute low-back pain with piroxicam: Results of a double-blind placebo-controlled trial. *Spine* 1987;12:473-6.
6. Arbus L, Fajadet B, Aubert D, Morre M, Goldberger E. Activity of tetrazepam (myolastan) in low back pain: A double-blind trial vs placebo. *Clin Trials Journal* 1990;27:258-67.
7. Arkuszewski Z. The efficacy of manual treatment in low back pain: A clinical trial. *Manual Medicine* 1986;2:68-71.
8. Asfour SS, Khalil TM, Waly SM, Goldberg ML, Rosomoff RS, Rosomoff HL. Biofeedback in back muscle strengthening. *Spine* 1990;15:510-3.
9. Bakshi R, Thumb N, Bröll H, et al. Treatment of acute lumbosacral back pain with diclofenac resinate: Results of a double-blind comparative trial versus piroxicam. *Drug Investigation* 1994;8:288-93.
10. Baratta RR. A double-blind study of cyclobenzaprine and placebo in the treatment of acute musculoskeletal conditions of the low back. *Current Therapeutic Research* 1982;32:646-52.
11. Bergquist-Ullman M, Larsson U. Acute low-back pain in industry: A controlled prospective study with special reference to therapy and confounding factors. *Acta Orthop Scand* 1977;170 (suppl):1-117.
12. Berry H, Bloom B, Hamilton EBD, Swinson DR. Naproxen sodium, Diflunisal, and placebo in the treatment of chronic back pain. *Ann Rheum Dis* 1982;41:129-32.
13. Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. *J Int Med Res* 1988;16:75-82.
14. Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low-back pain: Results of a double-blind multicentre study in general practice. *J Int Med Res* 1988;16:83-91.
15. Bigos S, Bowyer O, Braen G, et al. Acute low back problems in adults. Clinical practice guideline no. 14. AHCPR Publication no. 95-0642. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. December 1994.
16. Blazek M, Keszthelyi B, Varhelyi M, Korosi O. Comparative study of Blarison and Voltaren in acute lumbar pain and lumbo-ischialgia. *Ther Hung* 1986;34:163-6.
17. Blomberg S, Svardsudd K, Mildenerger F. A controlled multicentre trial of manual therapy in low-back pain. *Scand J Prim Health Care* 1992;10:170-8.
18. Blomberg S, Svardsudd K, Tibblin G. Manual therapy with steroid injections in low-back pain. *Scand J Prim Health Care* 1993;11:83-90.
19. Blomberg S, Hallin G, Grann K, Berg E, Sennerby U. Manual therapy with steroid injections—A new approach to treatment with low-back pain. *Spine* 1994;19:569-77.
20. Borenstein DG, Lacks S, Wiesel SW. Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. *Clin Ther* 1990;12:125-31.
21. Boyles WF, Glassman JM, Soyka JP. Management of acute musculoskeletal conditions: Thoracolumbar strain or sprain. A double-blind evaluation comparing the efficacy and safety of carisoprodol with diazepam. *Today's Therapeutic Trends* 1983;1:1-16.
22. Breivik H, Hesla PE, Molnar I, Lind B. Treatment of chronic low back pain and sciatica: Comparison of caudal epidural injections of bupivacaine and methylprednisolone with bupivacaine followed by saline. *Advances in Pain Research and Therapy* 1976;1:927-32.
23. Brown FL, Bodison S, Dixon J, Davis W, Nowoslawski J. Comparison of Diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain. *Clin Ther* 1986;9(suppl c):52-8.
24. Bush C, Ditto B, Feuerstein M. A controlled evaluation of paraspinal EMG biofeedback in the treatment of chronic low back pain. *Health Psychol* 1985;4:307-21.
25. Bush K, Hillier S. A controlled study of caudal epidural injections of triamcinolone plus procaine for the management of intractable sciatica. *Spine* 1991;16:572-5.
26. Buswell J. Low back pain: A comparison of two treatment programmes. *New Zealand Journal of Physiotherapy* 1982;10:13-7.
27. Casale R. Acute low back pain: Symptomatic treatment with a muscle relaxant drug. *Clin J Pain* 1988;4:81-8.
28. Coan RM, Wong G, Liang Ku S, Chong Chan Y, Wang L, Ozer FT, Coan PL. The acupuncture treatment of low back pain: A randomized controlled study. *Am J Chin Med* 1980;8:181-9.
29. Cuckler JM, Bernini PA, Wiesel SH, Booth RE, Rothman RH, Pickens GP. The use of steroids in the treatment of lumbar radicular pain. *J Bone Joint Surg* 1985;67:63-6.
30. Dapas F, Hartman SF, Martinez L, et al. Baclofen for the treatment of acute low-back syndrome: A double blind comparison with placebo. *Spine* 1985;10:345-9.
31. Davies JR, Gibson T, Tester L. The value of exercises in the treatment of low back pain. *Rheumatol Rehabil* 1979;18:243-7.
32. Delitto A, Cibulka MT, Erhard RE, Bowling RW, Tenhula JA. Evidence for use of an extension-mobilization category in acute low back syndrome: A prescriptive validation pilot study. *Phys Ther* 1993;73:216-28.
33. Deyo RA, Diehl AK, Rosenthal M. How many days of bed rest for acute low-back pain? A randomized clinical trial. *N Engl J Med* 1986;315:1064-70.
34. Deyo RA, Walsh NE, Martin DC, Schoenfeld LS, Ramamurthy S. A controlled trial of transcutaneous electrical nerve stimulation (TENS) and exercise for chronic low back pain. *N Engl J Med* 1990;322:1627-34.
35. Dickersin K. The existence of publication bias and risk factors for its occurrence. *JAMA* 1990;263:1385-9.
36. Donaldson S, Romney D, Donaldson M, Skubick D. Randomized study of the application of single motor unit biofeedback training to chronic low back pain. *J Occup Rehabil* 1994;4:23-37.
37. Donchin M, Woolf O, Kaplan L, Floman Y. Secondary prevention of low-back pain. A clinical trial. *Spine* 1990;15:1317-20.
38. Edelist G, Gross AE, Langer F. Treatment of low back pain with acupuncture. *Can Anaesth Soc J* 1976;23:303-6.
39. Elnaggar IM, Nordin M, Sheikhzadeh A, Parnianpour M, Kahanovitz N. Effects of spinal flexion and extension exercises on low-back pain and spinal mobility in chronic mechanical low-back pain patients. *Spine* 1991;16:967-72.
40. Evans C, Gilbert JR, Taylor W, Hildebrand A. A random-

ized controlled trial of flexion exercises, education, and bed rest for patients with acute low-back pain. *Physiotherapy Canada* 1987;39:96-101.

41. Evans DP, Burke MS, Lloyd KN, Roberts EE, Roberts GM. Lumbar spinal manipulation on trial. Part 1: Clinical assessment. *Rheumatology and Rehabilitation* 1978;17:46-53.

42. Evans DP, Burke MS, Newcombe RG. Medicines of choice in low back pain. *Curr Med Res Opin* 1980;6:540-7.

43. Faas A, Chavannes AW, Van Eijk JThM, Gubbels JW. A randomized, placebo-controlled trial of exercise therapy in patients with acute low back pain. *Spine* 1993;18:1388-95.

44. Faas A, Van Eijk JThM, Chavannes AW, Gubbels JW. A randomized trial of exercise therapy in patients with acute low back pain. *Spine* 1995;20:941-7.

45. Farrell JP, Twomey LT. Acute low-back pain: Comparison of two conservative treatment approaches. *Med J Aust* 1982;1:160-4.

46. Fordyce WE, Brockway JA, Bergman JA, Spengler D. Acute back pain: A control-group comparison of behavioral vs traditional management methods. *J Behav Med* 1986;9:127-40.

47. Frost H, Klaber Moffet JA, Moser JS, Fairbank JCT. Randomised controlled trial for evaluation of fitness programme for patients with chronic low back pain. *BMJ* 1995;310:151-4.

48. Gibson T, Grahame R, Harkness J, Woo P, Blagrove P, Hills R. Controlled comparison of short-wave diathermy treatment with osteopathic treatment in non-specific low-back pain. *Lancet* 1985;1258-61.

49. Gilbert JR, Taylor DW, Hildebrand A, Evans C. Clinical practice of common treatments for low-back pain. *Br Med J* 1985;291:789-92.

50. Glover JR, Morris JG, Khosla T. Back pain: A randomized clinical trial of rotational manipulation of the trunk. *Br J Ind Med* 1974;31:59-64.

51. Godfrey CM, Morgan PP, Schatzker J. A randomized trial of manipulation for low-back pain in a medical setting. *Spine* 1984;9:301-4.

52. Gold RH. Orphenadrine citrate: Sedative or muscle relaxant? *Clin Ther* 1978;1:451-3.

53. Goldie I. A clinical trial with indomethacin (Indomee) in low back pain and sciatica. *Acta Orthop Scand* 1968;39:117-28.

54. Goodkin K, Gullion CM, Agras S. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. *J Clin Psychopharmacol* 1990;10:269-78.

55. Gunn CC, Milbrandt WE, Little AS, Mason KE. Dry needling of muscle motor points for chronic low-back pain: A randomized clinical trials with long-term follow-up. *Spine* 1980;5:279-91.

56. Hackett GI, Seddon D, Kaminski D. Electroacupuncture compared with paracetamol for acute low back pain. *Practitioner* 1988;232:163-4.

57. Hadler NM, Curtis P, Gillings DB, Stinnett S. A benefit of spinal manipulation as adjunctive therapy for acute low-back pain: A stratified controlled trial. *Spine* 1987;12:703-5.

58. Hansen FR, Bendix T, Skov P, et al. Intensive, dynamic back-muscle exercises, conventional physiotherapy, or placebo-control treatment of low-back pain. *Spine* 1993;18:98-107.

59. Harkapaa K, Jarvikoski A, Mellin G, Hurri H. A con-

trolled study on the outcome of inpatient and outpatient treatment of low-back pain. Part I. *Scan J Rehab Med* 1989;21:81-9.

60. Harkapaa K, Mellin G, Jarvikoski A, Hurri H. A controlled study on the outcome of inpatient and outpatient treatment of low-back pain. Part III. *Scan J Rehab Med* 1990;22:181-8.

61. Heijden GJMG van der, Beurskens AJHM, Dirx MJM, Bouter LM, Lindeman E. Efficacy of lumbar traction: A randomised clinical trial. *Physiotherapy* 1995;81:29-35.

62. Helliwell PS, Cunliffe G. Manipulation in low-back pain. *The Physician* 1987;April:187-8.

63. Herman E, Williams R, Stratford P, Fargas-Babjak A, Trott M. A randomized controlled trial of transcutaneous electrical nerve stimulation (CODETRON) to determine its benefits in a rehabilitation program for acute occupational low back pain. *Spine* 1994;19:561-8.

64. Herzog W, Conway PJW, Willcox BJ. Effects of different treatment modalities on gait symmetry and clinical measures for sacroiliac joint patients. *J Manipulative Physiol Ther* 1991;14:104-9.

65. Hickey RF. Chronic low back pain: A comparison of diflunisal with paracetamol. *N Z Med J* 1982;95:312-4.

66. Hindle TH. Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome. *Calif Med* 1972;117:7-11.

67. Hingorani K. Diazepam in backache: A double-blind controlled trial. *Ann Phys Med* 1965;8:303-6.

68. Hosie GAC. The topical NSAID, felbinac, versus oral ibuprofen: A comparison of efficacy in the treatment of acute lower back injury. *Br J Clin Res* 1993;4:5-17.

69. Hurri H. The Swedish back school in chronic low-back pain. Part I. Benefits. *Scand J Rehab Med* 1989;21:33-40.

70. Hurri H. The Swedish back school in chronic low-back pain. Part II. Factors predicting the outcome. *Scand J Rehab Med* 1989;21:41-4.

71. Jenkins DG, Ebbutt AF, Evans CD. Trofanil in the treatment of low back pain. *J Int Med Res* 1976;4(suppl 2):28-40.

72. Johanssen F, Remvig L, Kryger P, et al. Exercises for chronic low back pain: A clinical trial. *J Orthop Sports Phys Ther* 1995;22:52-9.

73. Julkunen J, Hurri H, Kankainen J. Psychological factors in the treatment of chronic low back pain: Follow-up study of a back school intervention. *Psychother Psychosom* 1988;50:173-81.

74. Keijsers JFEM, Groenman NH, Gerards FM, Oudheusden van E, Steenbakkers WHL. A back school in the Netherlands. Evaluating the results. *Patient Education and Counseling* 1989;14:31-44.

75. Keijsers JFME, Steenbakkers WHL, Meertens RM, Bouter LM, Kok GJ. The efficacy of the back school: A randomized trial. *Arthritis Care and Research* 1990;3:204-9.

76. Kendall PH, Jenkins JM. Exercises for backache: A double-blind controlled trial. *Physiotherapy* 1968;54:154-7.

77. Klaber Moffett JA, Chase SM, Portek I, Ennis JR. A controlled prospective study to evaluate the effectiveness of a back school in the relief of chronic low-back pain. *Spine* 1986;11:120-2.

78. Koes BW, Bouter LM, Beckerman H, Heijden GJMG van der, Knipschild PG. Physiotherapy exercises and back pain: A blinded review. *Br Med J* 1991;302:1572-6.

79. Koes BW, Assendelft WJJ, Heijden GJMG van der,

Bouter LM, Knipschild PG. Spinal manipulation and mobilization for back and neck pain: A blinded review. *Br Med J* 1991; 303:1298-1303.

80. Koes BW, Bouter LM, Mameren van H, et al. The effectiveness of manual therapy, physiotherapy and treatment by the general practitioner for non-specific back and neck complaints: A randomized clinical trial. *Spine* 1992;17:28-35.

81. Koes BW, Bouter LM, Knipschild PG, et al. A blinded randomized clinical trial of manual therapy and physiotherapy for chronic back and neck complaints: Physical outcome measures. *J Manipulative Physiol Ther* 1992;15:16-23.

82. Koes BW, Bouter LM, Mameren H van, et al. Randomised clinical trial of manual therapy and physiotherapy for persistent back and neck complaints: Results of one year follow-up. *Br Med J* 1992;304:601-5.

83. Koes BW, Bouter LM, van Mameren H, et al. A randomized clinical trial of manual therapy and physiotherapy for persistent back and neck complaints: Subgroup analysis and relationship between outcome measures. *J Manipulative Physiol Ther* 1993;16:211-9.

84. Koes BW, Tulder MW van, Windt DAWM van der, Bouter LM. The efficacy of back schools: A review of randomized clinical trials. *J Clin Epidemiol* 1994;47:851-62.

85. Koes BW, Hoogen HMM van den. Efficacy of bed rest and orthoses for low back pain: A review of randomized clinical trials. *Eur J Phys Med Rehabil* 1994;4:86-93.

86. Koes BW, Bouter LM, Heijden GJMG van der. Methodological quality of randomized clinical trials on treatment efficacy in low back pain. *Spine* 1995;20:228-35.

87. Lacey PH, Dodd GD, Shannon DJ. A double-blind placebo controlled study of Piroxicam in the management of acute musculoskeletal disorders. *Eur J Rheumatol Inflamm* 1984;7: 95-104.

88. Lankhorst GJ, Stadt van der RJ, Vogelaar TW, Korst van der JK, Prevo AJH. The effect of the Swedish back school in chronic idiopathic low-back pain. *Scand J Rehab Med* 1983;15: 141-5.

89. Larsson U, Chöler U, Lidström A, et al. Auto-traction for treatment of lumbago-sciatica. *Acta Orthop Scand* 1980;51: 791-8.

90. Lehmann TR, Russell DW, Spratt KF. The impact of patients with nonorganic physical findings on a controlled trial of transcutaneous electrical nerve stimulation and electroacupuncture. *Spine* 1983;8:625-34.

91. Lehmann TR, Russell DW, Spratt KF, et al. Efficacy of electroacupuncture and TENS in the rehabilitation of chronic low back pain patients. *Pain* 1986;26:277-90.

92. Lidström A, Zachrisson M. Physical therapy on low back pain and sciatica: An attempt at evaluation. *Scand J Rehabil Med* 1970;2:37-42.

93. Lindequist SL, Lundberg B, Wikmark R, Bergstad B, Loof G, Ottermark AC. Information and regime at low-back pain. *Scand J Rehabil Med* 1984;16:113-6.

94. Lindström I, Ohlund C, Eek C, et al. The effect of graded activity on patients with subacute low back pain: A randomized prospective clinical study with an operant-conditioning behavioral approach. *Phys Ther* 1992;72:279-93.

95. Lindström I, Ohlund C, Eek C, Wallin L, Peterson L-E, Nachemson A. Mobility, strength, and fitness after a graded activity program for patients with subacute low back pain. *Spine* 1992;17:641-52.

96. Linton SJ, Bradley LA, Jensen I, Sprangfort, Sundell L.

The secondary prevention of low-back pain. A controlled study with follow-up. *Pain* 1989;36:197-207.

97. MacDonald AJR, MacRae KD, Master BR, Rubin AP. Superficial acupuncture in the relief of chronic low back pain. *Ann Roy Coll Surg Engl* 1983;65:44-6.

98. MacDonald RS, Bell CMJ. An open controlled assessment of osteopathic manipulation in nonspecific low-back pain. *Spine* 1990;15:364-70.

99. Malmivaara A, Häkkinen U, Aro T, et al. The treatment of acute low back pain—Bed rest, exercises, or ordinary activity? *N Engl J Med* 1995;332:351-5.

100. Manniche C, Hesselsoe G, Bentzen L, Christensen I, Lundberg E. Clinical trial of intensive muscle training for chronic low back pain. *Lancet* 1988;2:1473-6.

101. Manniche C, Lundberg E, Christensen I, Bentzen L, Hesselsoe G. Intensive dynamic back exercises for chronic low back pain: A clinical trial. *Pain* 1991;47:53-63.

102. Manniche C, Asmussen K, Lauritsen B, et al. Intensive dynamic back exercises with or without hyperextension in chronic back pain after surgery for lumbar disc protrusion: A clinical trial. *Spine* 1993;18:560-7.

103. Marchand S, Charest J, Li J, Chenard JR, Lavignolle B, Laurencelle L. Is TENS purely a placebo effect? A controlled study on chronic low back pain. *Pain* 1993;54:99-106.

104. Martin PR, Rose MJ, Nichols PJR, Russell PL, Hughes JG. Physiotherapy exercises for low back pain: Process and clinical outcome. *Int Rehabil Med* 1980;8:34-8.

105. Mathews JA, Hickling J. Lumbar traction: A double-blind controlled study for sciatica. *Rheumatol Rehabil* 1975; 14:222-5.

106. Mathews JA, Mills SB, Jenkins VM, et al. Back pain and sciatica: Controlled trials of manipulation, traction, sclerosant and epidural injections. *Br J Rheumatol* 1987;26:416-23.

107. Mathews W, Morkel M, Mathews J. Manipulation and traction for lumbago and sciatica: Physiotherapeutic techniques used in two controlled trials. *Physiother Practice* 1988; 4:201-6.

108. Matsumo S, Kaneda K, Nohara Y. Clinical evaluation of Ketoprofen (Orudis) in lumbago: A double blind comparison with diclofenac sodium. *Br J Clin Pract* 1991;35:266.

109. McCauley JD, Thelen MH, Frank RG, Willard RR, Callen E. Hypnosis compared to relaxation in the outpatient management of chronic low back pain. *Arch Phys Med Rehabil* 1983;64:548-52.

110. Mellin G, Hurri H, Harkapaa K, Jarvikoski A. A controlled study on the outcome of inpatient and outpatient treatment of low-back pain. Part II. *Scand J Rehabil Med* 1989;21: 91-5.

111. Mellin G, Harkapaa K, Hurri H, Jarvikoski A. A controlled study on the outcome of inpatient and outpatient treatment of low-back pain. Part IV. *Scand J Rehabil Med* 1990;22: 189-94.

112. Mendelson G, Kidson MA, Loh ST, Scott DF, Selwood TS, Kranz H. Acupuncture analgesia for chronic low back pain. *Clin Experiment Neurol* 1978;15:182-5.

113. Mendelson G, Selwood TS, Kranz H, Loh TS, Kidson MA, Scott DS. Acupuncture treatment of chronic back pain. *Am J Med* 1983;74:49-55.

114. Middleton RSW. A comparison of two analgesic muscle relaxant combinations in acute back pain. *Brit J Clin Pract* 1984;38:107-9.

115. Million R, Nilsen KH, Jayson MIV, Baker RD. Evalua-

- tion of low-back pain and assessment of lumbar corsets with and without back supports. *Ann Rheum Dis* 1981;40:449-54.
116. Moher D, Jadad AJ, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. *Control Clin Trials* 1995;16:62-73.
 117. Morrison GEC, Chase W, Young V, Roberts WL. Back pain. Treatment and prevention in a community hospital. *Arch Phys Med Rehabil* 1988;69:605-9.
 118. Nicholas MK, Wilson PH, Goyen J. Operant-behavioural and cognitive behavioural treatment for chronic low back pain. *Behav Res Ther* 1991;29:225-38.
 119. Nicholas MK, Wilson PH, Goyen J. Comparison of cognitive behavioral group treatment and an alternative non-psychological treatment for chronic low back pain. *Pain* 1992;48:339-47.
 120. Nouwen A. EMG biofeedback used to reduce standing levels of paraspinal muscle tension in chronic low back pain. *Pain* 1983;17:353-60.
 121. Nwuga VCB. Relative therapeutic efficacy of vertebral manipulation and conventional treatment in back pain management. *Am J Phys Med* 1982;61:273-8.
 122. Nwuga VCB. Ultrasound in treatment of back pain resulting from prolapsed intervertebral disc. *Arch Phys Med Rehabil* 1983;64:88-9.
 123. Nwuga G, Nwuga V. Relative therapeutic efficacy of the Williams and McKenzie protocols in back pain management. *Physiotherapy Practice* 1985;1:99-105.
 124. Ongley MJ, Klein RG, Dorman TA, Eek BC, Hubert LJ. A new approach to the treatment of chronic low-back pain. *Lancet* 1987;143-6.
 125. Orava S. Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. *Int J Clin Res* 1986;VI(1):45-51.
 126. Pheasant H, Bursk A, Goldfarb J, Azen SP, Weiss JN, Borelli L. Amitriptylene and chronic low-back pain: A randomized double-blind crossover study. *Spine* 1983;8:552-7.
 127. Postacchini F, Facchini M, Palieri P. Efficacy of various forms of conservative treatment in low back pain: A comparative study. *Neuro Orthop* 1988;6:28-35.
 128. Rasmussen GG. Manipulation in treatment of low-back pain: A randomized clinical trial. *Manual Medicine* 1979;1:8-10.
 129. Ridley MG, Kingsley G, Gibson T, Grahame R. Outpatient lumbar epidural corticosteroid injection in the management of sciatica. *Br J Rheumatol* 1988;27:295-9.
 130. Risch SV, Norvell NK, Pollock ML, et al. Lumbar strengthening in chronic low back pain patients: Physiologic psychological benefits. *Spine* 1993;18:232-8.
 131. Rocco AG, Frank E, Kaul AF, Lipson SJ, Gallo JP. Epidural steroids, epidural morphine and epidural steroids combined with morphine in the treatment of post laminectomy syndrome. *Pain* 1989;36:297-303.
 132. Rollings HE, Glassman JM, Soyka JP. Management of acute musculoskeletal conditions—Theracolumbar strain or sprain: A double-blind evaluation comparing the efficacy and safety of carisoprodol with cyclobenzaprine hydrochloride. *Curr Ther Res* 1983;34:917-28.
 133. Rosen M, Breen A, Hamann W, et al. Report of a Clinical Standards Advisory Group Committee on Back Pain. London, HMSO, May 1994.
 134. Sachs BL, Ahmad SS, LaCroix M, et al. Objective assessment for exercise treatment on the B-200 isostation as part of work tolerance rehabilitation: A random prospective blind evaluation with comparison control population. *Spine* 1994;19:49-52.
 135. Sanders GE, Reinert O, Tepe R, Maloney P. Chiropractic adjustive manipulation on subjects with acute low-back pain: Visual analog pain scores and plasma beta-endorphin levels. *J Manipulative Physiol Ther* 1990;13:391-5.
 136. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;273:408-12.
 137. Serrao JM, Marks RL, Morley SJ, Goodchild CS. Intrathecal midazolam for the treatment of chronic mechanical low back pain: A controlled comparison with epidural steroid in a pilot study. *Pain* 1992;48:5-12.
 138. Siegmeth W, Sieberer W. A comparison of the short-term effects of ibuprofen and diclofenac in spondylosis. *J Int Med Res* 1978;6:369-74.
 139. Spitzer WO, LeBlanc Fe, Dupuis M, eds. Scientific approach to the assessment and management of activity-related spinal disorders. *Spine* 1987;7(suppl):1-59.
 140. Stankovic R, Johnell O. Conservative treatment of acute low-back pain. A prospective randomized trial: McKenzie method of treatment versus patient education in "mini-back school." *Spine* 1990;15:120-3.
 141. Stankovic R, Johnell O. Conservative treatment of acute low back pain: A 5-year follow-up study of two methods of treatment. *Spine* 1995;20:469-72.
 142. Stuckey SJ, Jacobs A, Goldfarb J. EMG biofeedback training, relaxation training, and placebo for the relief of chronic back pain. *Percept Motor Skills* 1986;63:1023-36.
 143. Sweetman BJ, Baig A, Parsons DL. Mefenamic acid, chlormazanone-paracetamol, ethoptazine-aspirin-meprobamate: A comparative study in acute low back pain. *Br J Clin Pract* 1987;41:619-24.
 144. Szpalski M, Hayez JP. Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain. A double-blind placebo-controlled study. *Br J Rheumatol* 1994;33:74-8.
 145. Tervo T, Petaja L, Lepisto P. A controlled clinical trial of a muscle relaxant analgesic combination in the treatment of acute lumbago. *Br J Clin Pract* 1976;30:62-4.
 146. Triano JJ, McGregor M, Hondras MA, Brennan PC. Manipulative therapy versus education programs in chronic low-back pain. *Spine* 1995;20:948-55.
 147. Turner JA. Comparison of group progressive-relaxation training and cognitive-behavioral group therapy for chronic low back pain. *J Consult Clin Psychol* 1982;50:757-65.
 148. Turner JA, Clancy S. Comparison of operant behavioral and cognitive-behavioral group treatment for chronic low back pain. *J Consult Clin Psychol* 1988;56:261-6.
 149. Turner JA, Clancy S, McQuade KJ, Cardenas DD. Effectiveness of behavioral therapy for chronic low back pain: A component analysis. *J Consult Clin Psychol* 1990;58:573-9.
 150. Turner JA, Jensen MP. Efficacy of cognitive therapy for chronic low back pain. *Pain* 1993;52:169-77.
 151. van Tulder MW, Koes BW, Bouter LM. A cost-of-illness study of back pain in The Netherlands. *Pain* 1995;62:233-40.
 152. van Tulder MW, Koes BW, Bouter LM, eds. Low back pain in primary care: Effectiveness of diagnostic and therapeutic

tic interventions. EMGO-Institute, Vrije Universiteit, Amsterdam, 1996.

153. Videman T, Osterman K. Double-blind parallel study of Piroxicam versus Indomethacin in the treatment of low back pain. *Annals of Clinical Research* 1984;16:156-60.

154. Videman T, Heikkila J, Partanen T. Double-blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. *Curr Med Res Opin* 1984;9:246-52.

155. Waagen GN, Haldeman S, Cook G, Lopez D, DeBoer KF. Short term trial of chiropractic adjustments for the relief of chronic low-back pain. *Manual Medicine* 1986;2:63-7.

156. Waterworth RF, Hunter IA. An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain. *N Z Med J* 1985;98:372-5.

157. Weber H, Aasand G. The effect of phenylbutazone on patients with acute lumbago-sciatica: A double blind trial. *Journal of the Oslo City Hospital* 1980;30:69-72.

158. Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. *Spine* 1993;18:1433-8.

159. White AWM. Low back pain in men receiving workmen's compensation. *Can Med Assoc J* 1966;95:50-6.

160. Wiesel SW, Cuckler JM, Deluca F, Jones F, Zeide MS,

Rothman RH. Acute low back pain: An objective analysis of conservative therapy. *Spine* 1980;5:324-30.

161. Wilkinson MJB. Does 48 hours' bed rest influence the outcome of acute low back pain? *Br J Gen Pract* 1995;45:481-4.

162. Wilson MC, Hayward RSA, Tunis SR, Bass EB, Guyatt G, for the Evidence-Based Medicine Working Group. User's guides to the medical literature, VIII: How to use clinical practice guidelines, B: What are the recommendations and will they help you in caring for your patients? *JAMA* 1995;274:1630-2.

163. Wreje U, Nordgren B, Aberg H. Treatment of pelvic joint dysfunction in primary care: A controlled study. *Scand J Prim Care* 1992;10:310-5.

Address reprint requests to

Maurits W. van Tulder, PhD
Institute for Research in Extramural Medicine
Faculty of Medicine
Vrije Universiteit
Van der Boechorststraat 7
1081 BT Amsterdam, The Netherlands
E-mail: mw.vantulder.emgo@med.vu.nl

■ Appendix

Table 6. Details of Randomized Controlled Trials on the Effectiveness of Analgesics for Acute Low Back Pain

Reference	Analgesics Dose/Frequency/Duration (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Videman ¹⁵⁴	(I) Meptazinol 200 mg qid/3 wk (35)	(R) Diflunisal 250 mg qid/4 wk (35)	Mean change in degree of pain (100 mm VAS) at 3 wk (I) 45 vs. (R) 40; similar improvement regarding capacity for daily tasks (data in graphs); no significant differences; side effects similar (I) 19 vs. (R) 23 patients
Wiesel ¹⁶⁰	(I1) Acetaminophen (dosage not given)/bid/2 wk (?)		Mean (SD) no. of days before return to full activity (I1) 5.6 (0.6), (I2) 5.2 (0.6), (I3) 5.6 (0.7); no significant differences; no data on side effects given
Brown ²³	(I2) Codeine 60 mg qid/2 wk (?) (I3) Oxycodone + aspirin 1 tablet qid (?) (I) Acetaminophen 300 mg + codeine 50 mg/2 caps initially, one caps every 4 hr/15 days (21)	(R) Diflunisal (caps) initial dose 1000 mg; 500 mg every 12 hr/15 days (19)	Pain assessment by patient and investigator on 3-point ordinal scale shows similar improvement curves (data in graphs); no. of patients rating drugs as excellent or very good (I) 9 vs. (R); no significant differences; more side effects in (I) 10 than in (R) 3
Evans ⁴²	(I1) Dextropropoxyphene 32.5 mg + paracetamol 325 mg/2 caps qid/1 wk (30 c.o.) (I2) Paracetamol 500 mg/2 caps qid/1 wk (30 c.o.)	(R1) Aspirin 300 mg 3 caps qid/1 wk (30 c.o.) (R2) Indomethacin 50 mg tid/1 wk (30 c.o.) (R3) Mefenamic acid 250 mg 2 caps tid/1 wk (30 c.o.) (R4) Phenylbutazone 100 mg tid/1 wk (30 c.o.)	Mean daily pain index during intervention period (4-point ordinal scale) (I1) 1.7, (I2) 1.7, (R1) 1.4, (R2) 1.5, (R3) 1.4, (R4) 1.4; (R3) significantly different from (I1 and I2); (R1) significantly different from (I1); more side effects in (R1) 20, (R2) 19, and (I1) 19 than in (R3) 12, (I2) 13, and (R4) 4
Hackett ⁵⁶	(I) Paracetamol 2 tablets every 4 hr (?)	(R) Electroacupuncture 2 treatments in 4 days (?)	Pain scores (VAS) pretreatment and after 1, 2, and 6 wk: (I) 54.5, 23.4, 22.0, 13.7 vs. (R) 52.7, 23.2, 18.3, 3.3; (R) significantly less pain after 6 wk
Nwuga ¹²²	(I) Analgesics (unspecified) (?)	(R1) Ultrasound (?) (R2) Placebo ultrasound (?)	Proportion of patients pain-free after 4 wk (I) 6.8%, (R1) 40.7%, (R2) 12%; (R1) significantly more improved than (I)

bid = twice per day; qid = four times per day; caps = capsules; c.o. = cross-over; ? = number of patients not given.

Table 7. Details of Randomized Controlled Trials on the Effectiveness of NSAIDs for Acute Low Back Pain

Reference	NSAIDs Dose/Frequency/Duration (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Hosie ⁶⁸	(I1) Ibuprofen caps 400 mg tid + placebo foam tid/14 days (147) (I2) Felbinac (foam 3%) tid + placebo caps tid/14 days (140)		Patients (%) reporting none or mild severity after 1 and 2 wk (I1) 84, 92, (I2) 76, 88; no significant differences; no. of side effects (I1) 22, (I2) 26
Amlie ⁵	(I) Piroxicam 20 mg caps bid first 2 days, one daily next 5 days/7 days (140)	(R) Placebo caps (142)	(I) More pain relief (VAS) than (R) after 3 days; after 7 days no significant differences; side effects similar (I) 13%, (R) 17%
Goldie ⁵³	(I) Indomethacin 25 mg caps tid/course of 50 caps (25)	(R) Placebo caps (25)	No. of patients with complete relief of pain after 7 and 14 days (I) 7, 14 (R) 9, 16; no significant differences; side effects similar (I) 8, (R) 5
Weber ¹⁵⁸	(I) Piroxicam 20 mg caps/40 mg per day first 2 days; 20 mg per day next 12 days/14 days (120)	(R) Placebo caps (94)	Reduction of pain in back and leg measured by visual analogue scales after 4 wk the same in the two groups (data in graphs); no significant differences; more side effects in (I) 22 than in (R) 13
Bakshi ⁹	(I1) Diclofenac resinate caps 75 mg bid/14 days (66) (I2) Piroxicam caps 20 mg bid for 2 days + once daily for 12 days (66)		Mean pain intensity scores at rest (VAS) pre- and post-treatment: (I1) 70.0, 22.7, (I2) 67.1, 21.0; efficacy excellent or good according to patients: (I1) 81.8%, (I2) 87.7%; no differences; side effects similar (I1) 17, (I2) 15
Blazek ¹⁶	(I1) Diclofenac 25 mg caps/qid first 4 days and tid next 8 days/12 day (14) (I2) Briarison 300 mg caps/qid first 4 days and tid next 8 days/12 days (14)		Average improvement on 5-point ordinal scale (0 = no response, 4 = very good response) during and after the intervention period of 12 days according to physician and patient: (I1) 2.6 and 2.8, (I2) 2.8 and 3; no significant differences in recovery rate; side effects: mild side effects in 3 patients in each group
Szpalski ¹⁴⁴	(I) Tenoxicam 20 mg i.m. injection on day 1 + 20 mg caps 1 day for day 2–14 (+7 days bed rest) (37)	(R) Placebo injection + placebo caps (36)	Mean pain intensity (VAS) on day 1, 8, and 15 (I) 7.4, 1.9, 0.6 (R) 7.1, 2.8, 0.8; (I) significantly better on day 8; side effects: one patient in group (I)
Lacey ⁸⁷	(I) Piroxicam 10 mg caps/qid first 2 days, bid next 12 days/14 days (168)	(R) Placebo caps (169)	Patients (%) improved after 1 wk only in subgroups with initial moderate/severe pain (I) 82%/49%, (R) 53%/38%; no differences for subgroup with mild initial pain; results after 2 wk not reported, and no data presented on side effects for subgroup with back pain
Videman ¹⁵⁴	(I) Diflunisal 250 mg caps qid/3 wk (35)	(R) Meptazinol 200 mg caps qid/3 wk (35)	Mean change in pain (100 mm VAS) at 3 wk: (I) 45, (R) 40; similar improvement regarding capacity for daily tasks (data in graphs); no significant differences; side effects similar: (I) 19, (R) 23 patients
Sweetman ¹⁴³	(I) Mefenamic acid 500 mg tid + placebo bid (40)	(R1) Chlormezanone 100 mg and paracetamol 450 mg two caps tid + placebo tid (42) (R2) Ethoheptazine 75 mg and meprobamate 150 mg and aspirin 250 mg two caps + placebo tid (40)	No. of patients reporting no pain after 1 and 7 days (I) 7, 21, (R1) 12, 23; (R2) 10, 20; no. of patients with adverse events: (I) 9; (R1) 10; (R2) 16
Orava ¹²⁵	(I1) Diflunisal 500 mg caps bid/7 days (66) (I2) Indomethacin 50 mg caps tid/7 days (67)		No. of patients (%) assessing therapy as good or excellent after 3 and 7 days (I1) 45%, 64%, (I2) 45%, 64%; no significant differences; more side effects in (I2) 31% than in (I1) 18%
Wiesel ¹⁶⁰	(I1) Aspirin 625 mg caps qid/2 wk (?) (I2) Phenylbutazone 100 mg caps qid (first 5 days); no further information given (?)	(R) Acetaminophen (dosage not given) bid (2 wk) (?)	Mean no. of days before return to full activity (I1) 5.7; (I2) 6.5; (R) 5.7; no significant differences; no data on side effects given
Agrifoglio ²	(I1) Aceclofenac 150 mg im injection bid 2 days + tablet 100 mg bid 5 days (50) (I2) Diclofenac 75 mg im injection bid 2 days + tablet 50 mg tid 5 days (50)		No significant difference in pain intensity (VAS) pre- and posttreatment (data in graph); percentage of patients not limited in functional impairment posttreatment: (I1) 65.9%, (I2) 40.5%; significant; overall assessment of efficacy good/very good: (I1) 85%, (I2) 76%; significant; side effects: (I1) 1, (I2) 8
Weber ¹⁵⁷	(I) Phenylbutazone 200 mg/2 caps tid for 3 days; 1 caps tid next 2 days (28)	(R) Placebo caps (29)	No. of patients reporting definite positive effect after intervention period (I) 14, (R) 8; no significant differences; no side effects reported by the patients
Waterworth ¹⁵⁶	(I) Diflunisal 500 mg caps 1000 mg immediately; 500 mg bid/10 days (36)	(R1) Physiotherapy: local heat, ultrasound and exercises, 5 × 45-min session weekly (34) (R2) Spinal manipulation and/or McKenzie therapy, 5 × 45-min sessions weekly (38)	Mean change in pain intensity on 4-point scale after 4 and 12 days: (I) -0.9, -1.7; (R1) -0.9, -1.6; (R2) -1.1, -1.7; no significant differences in pain and mobility

Reference	NSAIDs Dose/Frequency/Duration (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Brown ²³	(I) Diflunisal caps/initial dose 1000 mg; 500 mg every 12 hr/15 days (19)	(R) Acetaminophen 300 mg with codeine 50 mg/2 caps initially; 1 caps every 4 hr/15 days (21)	Pain assessment by patient and investigator on 3-point ordinal scale shows similar improvement curves (data in graphs); no. of patients rating drugs as excellent or very good: (I) 9, (R) 9; no significant differences; side effects: more side effects in (R) 10 than in (I) 3
Evans ⁴²	(I1) Aspirin 300 mg/3 caps qid/1 wk (30) (I2) Indomethacin 50 mg tid/1 wk (30) (I3) Mefenamic acid 250 mg/2 caps tid/1 wk (30) (I4) Phenylbutazone 100 mg tid/1 wk (30)	(R1) Dextropropoxyphene 32.5 mg + paracetamol 325 mg caps/2 caps qid/1 wk (30) (R2) Paracetamol 500 mg/2 caps qid/1 wk (30)	Mean daily pain index during intervention period (on 4-point ordinal scale): (I1) 1.4, (I2) 1.5, (I3) 1.4, (I4) 1.4, (R1) 1.7, (R2) 1.7; (I3) significantly different from (R1 and R2); (I1) significantly different from (R1); side effects: more side effects in (I1) 20, (I2) 19, (R1) 19 than in (I3) 12, (R2) 13, (I4) 4
Aghababian ¹	(I1) Diflunisal caps/1000 mg initially, 500 mg every 8–12 hr/2 wk (16) (I2) Naproxen caps/500 mg initially, 250 mg every 6–8 hr/2 wk (17)		No. of patients (%) reporting no pain (4-point ordinal scale) after 2 wk: (I1) 81%, (I2) 41%; no significance tests reported; no adverse experiences were reported by the patients
Postacchini ¹²⁷	(I) Diclofenac “full dosage”/10–14 days (34)	(R1) Chiropractic manipulation (35) (R2) Physiotherapy (31) (R3) Bed rest (29) (R4) Placebo (antiedema gel) (30)	Mean improvement on combined pain, disability, and spi- nal mobility score (5–32) after 3 wk, 2 and 6 mo: (I) 3.0, 10.7, 14.0; (R1) 7.5, 9.7, 12.3; (R2) 5.0, 8.4, 10.2; (R3) 5.4, 7.5, 7.3; (R4) 1.8, 7.3, 11.0; (R1) significantly better than others after 3 wk; no other differences; no data on side effects reported

bid = twice per day; tid = three times per day; qid = four times per day; caps = capsules; ? = number of patients not given; NSAIDs = nonsteroidal anti-inflammatory drugs.

Table 8. Details of Randomized Controlled Trials on the Effectiveness of Muscle Relaxants for Acute Low Back Pain

Reference	Muscle Relaxants Dose/ Frequency/Duration (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Berry ¹⁴	(I) Tizanidine 4 mg plus ibuprofen 400 mg tid/7 days (51)	(R) Placebo plus ibuprofen 400 mg tid/7 days (54)	Mean changes (SD) in pain score (VAS 100 mm) after 3 days (I) pain at night 20 (32.8), pain at rest 18 (25.3), and pain walking 23 (25.4) vs. (R) 22 (34.6), 16 (24.9) and 13 (22.6); after 7 days (I) 32 (39.5), 29 (43.3) and 36 (34.1) vs. (R) 33 (39.8), 33 (32.9) and 30 (32.8); percentage of patients im- proved after 3 days (I) 76% vs. (R) 67%, and after 7 days (I) 85% vs. (R) 81%; no significant differences; (I) signifi- cantly more central nervous system side effects, (R) signifi- cantly more gastrointestinal side effects; significantly fewer patients had moderate or severe pain at rest or pain at night in (I) than in (R)
Baratta ¹⁰	(I) Cyclobenzaprine 10 mg tid–qid/10 days (58)	(R) Placebo tid–qid/10 days (59)	Mean decrease in pain (10-point scale) from day 1 to 9 (I) –0.8 to –5.5 vs. (R) –0.3 to –4.0; (I) significantly better; moderate to marked global improvement (I) 71% vs. (R) 25%, significant; significantly more central nervous side effects in (I)
Casale ²⁷	(I) Dantrolene sodium 25 mg 1 caps per day/4 days (10)	(R) Placebo 1 caps per day/4 days (10)	Pain during maximal voluntary movement (VAS) decreased significantly more in (I) than in (R); muscle spasm signifi- cantly more improved in (I) 85% than in (R) 30%
Boyles ²¹	(I1) Carisoprodol 350 mg qid/8 days (36)	(I2) Diazepam 5 mg qid/8 days (35)	Patient’s assessment of muscle tension, stiffness, and overall relief significantly more improved in (I1) than in (I2) after 6 and 7 days; no significant difference in pain; physician’s assessment of overall improvement and muscle spasm significantly better in (I1) than in (I2) after 7 days, but not after 3 days; data in graphs
Hindle ⁶⁶	(I) Carisoprodol 350 mg qid/4 days (16)	(R1) Placebo qid/4 days (16) (R2) Butabarbital 15 mg/qid/4 days (16)	Pain score (VAS 0–100) at baseline and after 2 and 4 days (I) 86.0, 33.0, and 15.5, (R1) 65.5, 58.5, and 64.0, (R2) 75.2, 58.7, and 49.1; (I) significantly more improved; ADL significantly more improved in (I) than in (R1) and (R2), but not muscle spasm
Middleton ¹¹⁴	(I1) Methocarbamol 400 mg plus acetyl sali- cylic acid 325 mg/2 tabl qid/7 days (55)	(I2) Chlormezanone 100 mg plus paracetamol 450 mg/2 tabl tid/7 days (52)	Percentage of patients with moderate to very severe pain on day 1 and day 7 in (I1) 87% and 51% vs. (I2) 85% and 52%; percentage of patients with overall improvement posttreat- ment (I1) 66% vs. (I2) 61%; not significant; significantly more side effects in (I2) than (I1)
Dapas ³⁰	(I) Baclofen 10 mg/1–2 tabl tid–qid/10 days (100)	(R) Placebo 2 tabl qid/10 days (100)	For patients with severe symptoms at baseline, (I) signifi- cantly more improved at day 10 in pain, patient’s opinion, ADL, muscle spasm, and spinal mobility; significantly more side effects in (I)

Reference	Muscle Relaxants Dose/ Frequency/Duration (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Rollings ¹³²	(I1) Carisoprodol 350 mg qid/7 days (28)	(I2) Cyclobenzaprine HCL 10 mg qid/7 days (30)	No statistically significant differences between (I1) and (I2) on pain, muscle stiffness and tension, ADL, and overall relief, data in graphs
Berry ¹³	(I) Tizanidine 4 mg tid/7 days (59)	(R) Placebo tid/7 days (53)	Mean (SD) pain score (VAS 100 mm) at baseline and after 3 and 7 days: pain at night (I) 51 (31.5), 39 (32.3) and 15 (20.6) vs. (R) 52 (33.1), 38 (28.8) and 18 (20.8); pain at rest (I) 51 (29.4), 39 (29.6) and 19 (23.2) vs. (R) 51 (26.9), 34 (27.9) and 19 (22.9); pain on movement (I) 55 (30.0), 46 (30.4) and 18 (22.9) vs. (R) 49 (27.8), 36 (25.6) and 18 (23.1); no differences between (I) and (R); overall improvement after 3 and 7 days (I) 17% and 84% of patients and (R) 8% and 82% of patients; not significant; side effects in (I) 41% and (R) 21%; (I) significantly more central nervous system side effects, (R) significantly more gastrointestinal side effects
Gold ⁵²	(I) Orphenadrine citrate 100 mg bid/7 days (20)	(R1) Placebo bid/7 days (20) (R2) Phenobarbital 32 mg bid/7 days (20)	No. of patients improved after 2 days (I) 7, (R1) 0, (R2) 3; (I) significantly more improved than (R1); no. of patients with reduced pain after 2 days (I) 9, (R1) 4, (R2) 3; (I) significantly more reduced than (R1) and (R2); no. of patients with side effects (I) 5, (R1) 1, (R2) 2
Sweet- man ¹⁴³	(I) Chlormezanone 100 mg plus paracetamol 450 mg/2 caps tid/7 days (42)	(R1) Mefenamic acid 500 mg tid/7 days (40) (R2) Ethoheptazine 75 mg plus mep- robamate 150 mg plus aspirin 250 mg 2 tabl tid/7 days (40)	No. of patients with overall improvement after 7 days (I) 24, (R1) 24, (R2) 22; not significant; no. of patients reporting side effects on day 7 (I) 5, (R1) 5, (R2) 13; significant
Borenstein ²⁰	(I) Cyclobenzaprine 10 mg tid plus naproxen 500 mg initially, 250 mg qid/14 days (20)	(R) Naproxen 500 mg initially, 250 mg qid/14 days (20)	Treatment outcome significantly better on muscle spasm and tenderness in (I) than (R); no significant differences on pain and functional capacity; significantly more side effects in (I) than (R)
Hingorani ⁶⁷	(I) Diazepam 10 mg/4 im injections 24 hr plus 2 mg oral qid/5 days plus aspirin 10 g tid/5 days (25)	(R) Placebo 4 injections 24 hr plus oral qid/5 days plus aspirin 10 g tid/5 days (25)	No. of patients improved (I) 19 vs. (R) 18; side effects: drowsiness in (I) 7 patients vs. 3 in (R)
Tervo ¹⁴⁵	(I) Orphenadrine im in- jection 60 mg 2 ml plus oral orphenadrine citrate 35 mg plus paracetamol 450 mg/2 tabl tid/8 days (25)	(R) Placebo saline injection 2 ml plus oral paracetamol 450 mg/2 tabl tid/8 days (25)	No significant differences in subjective impression of improvement, muscle spasm, and spinal flexion; walking and sitting ability significantly more improved in (I) than (R); side effects in (I) 2 patients and (R) 1 patient

bid = twice per day; tid = three times per day; qid = four times per day; tabl = tablet; caps = capsules; ? = number of patients not given; ADL = activities of daily living.

Table 9. Details of Randomized Controlled Trials on the Effectiveness of Epidural Steroid Injections for Acute Low Back Pain

Reference	Epidural Steroid Injection (no. of patients)	Reference Treatment (no. of patients)	Results
Mathews ¹⁰⁶	(I) 80 mg (2 ml) methylprednisolone + 20 ml bupivacaine 0.125%, caudal route (23)	(R) 2 ml lignocaine, subcutaneously (34)	No. of patients recovered after 1 mo (I) 67%, (R) 56%; not significant; after 3 mo (I) significantly more pain-free than (R)

Table 10. Details of Randomized Controlled Trials on the Effectiveness of Bed Rest for Acute Low Back Pain

Reference	Treatment With Bed Rest (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Deyo ³³	(I1) Bed rest (2 days recommended) (101) (I2) Bed rest (7 days recommended) (102)		No differences in functional status, self-rated and clinician-rated improvement, and duration of pain after 3 wk and 3 mo; no. of days absent from work after 3 wk: (I1) 3.1, (I2) 5.6, significant
Gilbert/Evans ^{40,49}	(I1) Bed rest at least 4 days (instructed) (60) (I2) Bed rest at least 4 days (instructed) and physiotherapy and instruction (65)	(R1) Exercise and education (62) (R2) No intervention (65)	No. of patients reporting no pain after 6 and 12 wk: (I1) 34, 37, (I2) 33, 46, (R1) 36, 44, (R2) 33, 43; no significant differences in pain, mobility, or daily activities

Reference	Treatment With Bed Rest (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Malmivaara ⁹⁹	(I) Complete bed rest for 2 days, routine activities as tolerated thereafter (67)	(R) Continuation of ordinary activities as tolerated (67)	Differences in adjusted group means (95% CI) of (I) minus (R) on pain intensity (11-point scale), functional status (Oswestry), and satisfaction with treatment (11-point scale) after 3 wk 0.3 (−0.4 to 0.9), 3.9 (−0.2 to 8.0), and −0.7 (−1.8 to 0.4) and after 12 wk 0.7 (0.03 to 1.4), 3.8 (0.1 to 7.5), and −0.6 (−1.6 to 0.4); pain intensity and functional status significantly better in (I) after 12 wk
Wilkinson ¹⁶¹	(I) Complete bed rest for 48 hr (20)	(R) No daytime rest and remaining mobile (22)	Mean (SD) functional status (Roland) at day 1, 7, and 28: (I) 13.9 (5.4), 9.7 (19.9), 5.9 (5.6) and (R) 11.0 (11.0), 5.3 (5.7), 3.2 (4.0); (I) significantly more improved between day 7 and 28; no differences in mobility and time off work
Postacchini ¹²⁷	(I) 20–24 hr for the first 4–6 days and 15–20 hr a day for a further 2 days (29)	(R1) Manipulation (daily first week and then twice a week for 3 wk) (35) (R2) NSAIDs, 10–14 days (34) (R3) Physiotherapy: light massage, analgesic current and infrared: daily for 2–3 wk (31) (R4) Placebo: antiedema gel to be spread on the lumbar region twice a day for 1 or 2 wk (30)	Mean improvement on combined pain, disability, and spinal mobility score (range 5–32) after 3 wk, 2 and 6 mo; in subgroup with acute LBP only (I) 5.4, 7.5, 7.3, (R1) 7.5, 9.7, 12.3, (R2) 3.0, 10.7, 14.0, (R3) 5.0, 8.4, 10.2, (R4) 1.8, 7.3, 11.0; (R1) significantly better after 3 wk; no other differences
Wiesel ¹⁶⁰	(I) Bed rest in hospital for maximal 14 days (?)	(R) Ambulatory treatment without physical exercise (patients are kept on their feet) (?)	Average (SE) no. of pain points within 2 wk (I) 51.7 (5.3), (R) 107.6 (10.1), significant; no. of days (SE) before return to work (I) 6.6 (0.23), (R) 11.8 (0.12), significant

NSAIDs = nonsteroidal anti-inflammatory drugs.

Table 11. Details of Randomized Controlled Trials on the Effectiveness of Exercise Therapy for Acute Low Back Pain

Reference	Exercise Regimen (no. of patients)	Reference Treatment (no. of patients)	Results
Faas ^{43,44}	(I) Stretching, flexion, side movements, and advice (156)	(R1) Usual care by general practitioner: analgesics, information (155) (R2) Placebo ultrasound therapy (162)	No significant differences in no. of recurrences, duration of pain, or functional status (NHP) during 1 yr follow-up; only NHP-energy more improved in (I) than in (R1) during first 3 mo
Evans/Gilbert ^{40,49}	(I1) Isometric flexion, education, bed rest (65) (I2) Isometric flexion, and bed rest (62)	(R1) Bed rest (60) (R2) No intervention (65)	No. of patients reporting no pain after 6 and 12 wk: (I1) 34, 47, (I2) 33, 46, (R1) 36, 44, (R2) 33, 43; no significant differences in pain, mobility, or daily activities
Malmivaara ⁹⁹	(I) Mobilizing exercises: back-extension and lateral bending (52)	(R) Continuation of ordinary activities as tolerated (67)	Differences in adjusted group means (95% CI) between (I) and (R) on pain intensity (11-point scale), functional status (Oswestry), and satisfaction with treatment (11-point scale) after 3 wk 0.9 (−0.001 to 1.7), 6.6 (2.0 to 11.1), and 0.5 (−0.6 to 1.6) and after 12 wk 0.2 (−0.5 to 1.0), 2.6 (−1.6 to 6.7), and 0.4 (−0.6 to 1.4)
Stankovic ^{140,141}	(I) McKenzie extension (50)	(R) Mini-back school (50)	Significantly less pain and better spinal mobility in (I) at 3 wk and after 1 yr (no data); no. of recurrences after 1 and 5 yr significantly less in (I) 22/49, 30/47 than (R) 37/46, 37/42
Waterworth ¹⁵⁶	(I) Flexion and extension, shortwave diathermy and ultrasound (34)	(R1) NSAIDs (36) (R2) Manipulation (38)	Mean change in pain intensity on 4-point scale after 4 and 12 days: (I) −0.9, −1.6, (R1) −0.9, −1.7, (R2) −1.1, −1.7; no significant difference in pain or mobility
Nwuga ¹²¹	(I) Isometric flexion back and abdominal muscles and microwave diathermy (25)	(R) Manipulation (26)	Improvement in spinal flexion and SLR: (I) 13°, 4°, (R) 34°, 39°; manipulation significantly better than exercise
Farrell ⁴⁵	(I) Isometric flexion abdominal muscles in microwave diathermy (24)	(R) Manipulation and mobilization (24)	(R) symptom-free in significantly less days than (I)

Reference	Exercise Regimen (no. of patients)	Reference Treatment (no. of patients)	Results
Davies ³¹	(I1) Extension and shortwave diathermy (14) (I2) Isometric flexion and shortwave diathermy (14)	(R) Shortwave diathermy (15)	No. of patients showing improvement after 2 and 4 wk: (I1) 11, 13, (I2) 7, 12, (R) 8, 10; not significant
Delitto ³²	(I1) McKenzie extension and mobilization (14) (I2) Williams flexion (10)		(I1) significantly more improved on functional status (Oswestry) than (I2) after 3 and 5 days (data in graphs)
Nwuga ¹²³	(I1) McKenzie extension (31) (I2) Williams flexion (31)		Change in 10-point pain rating after 6 wk (I1) -5.3 vs (I2) -2.7; (I1) significantly better than (I2)

NSAIDs = nonsteroidal anti-inflammatory drugs; SLR = straight leg raising.

Table 12. Details of Randomized Controlled Trials on the Effectiveness of Back Schools for Acute Low Back Pain

Reference	Back School Program (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Bergquist ¹¹	(I) Swedish back school: 4 × 45 min in 2 wk (lessons include information on anatomy, causes of LBP, semi-Fowler position, ergonomics, exercises, and advice on physical activity) (70)	(R1) Combined physical therapy: manual therapy according to Cyriax, Kaltenborn, Lewitt, and Janda (72) (R2) "Placebo": short-waves at lowest intensity; a maximum of 10 treatments (75)	Mean number of days until recovery (I) 14.8 (R1) 15.8 (R2) 28.7; (I) significantly better than (R2), but not (R1); no differences in decrease of pain after 3 and 6 wk
Stankovic ^{140,141}	(I) Mini-back school: one lesson of 45 min on back care and education (50)	(R) McKenzie method: 20 min exercises and postural instructions to restore or maintain lumbar lordosis (50)	Less pain in (R) than (I) after 3 and 52 wk (no data)
Lindequist ⁹³	(I) Postural education "back school type" and training program supervised by physiotherapist (24)	(R) Advice not to strain the back and to use analgesics when needed; no physiotherapy (32)	Percentage of patients pain-free after 1, 3, and 6 wk: (I) 21, 75, 83 (R) 16, 66, 81; no significant differences
Morrison ¹¹⁷	(I) Outpatient back program including education (body mechanics, causes and remediation, psychological stress) and exercise (increasing physical strength and mobility): six 3-hr sessions over 2, 3, or 6 wk period (?)	(R) Control group (no further information) (?)	Significantly more improvement with regard to body mechanics, physical strength, mobility, and physical ability in (I) vs. (R) after the program

Table 13. Details of Randomized Controlled Trials on the Effectiveness of Spinal Manipulation for Acute Low Back Pain

Reference	Manipulation (no. of patients)	Reference Treatment (no. of patients)	Results
MacDonald ⁹⁸	(I) Osteopathic (49)	(R) Exercises and postural advice (46)	All patients: no significant different recovery rates between treatment groups; in subgroup with current attack duration of 2–4 wk: (I) 46% (R) 17% recovered after 1 wk
Sanders ¹³⁵	(I) Chiropractic (6)	(R1) No treatment (6) (R2) Sham manipulation (6)	Mean pain scores (VAS) slightly reduced in (I) 5 and 30 min after intervention; no changes found in (R1) or (R2); no statistics on group differences presented
Hadler ⁵⁷	(I) Rotational (26)	(R) Spinal mobilization (28)	All patients: no difference in functional status (Roland); in subgroup with current attack duration of 2–4 wk better results in manipulation group (I) after 1 wk
Bergquist ¹¹	(I) Cyriax, Kaltenborn, Lewitt, Janda (72)	(R1) Low intensity shortwave diathermy (75) (R2) Back school (70)	Mean no. of days until recovery (I) 15.8, (R1) 28.7, (R2) 14.8; (I) and (R2) significantly better than (R1); no significant differences (I) and (R2)
Mathews ¹⁰⁷	(I) Cyriax (165)	(R) Infrared heat (126)	Percentage of patients recovered after 2 wk in subgroup (n = 58) with SLR– 62% (I) vs. 70% (R), in subgroup (n = 233) with SLR+ 80% (I) vs. 67% (R); manipulation significantly better in subgroup with SLR+
Helliwell ⁶²	(I) Cyriax (6)	(R) Analgesics (8)	Combined symptom score (max 28) after 1 wk 2.6 ± 2.6 (I) vs. 3.8 ± 3.3 (R) and after 4 wk 6.1 ± 7.2 (I) vs. 2.2 ± 2.5 (R); no significant differences
Glover ⁵⁰	(I) Rotational (43)	(R) Detuned shortwave diathermy (41)	Pain relief on VAS posttreatment and after 3 and 7 days: (I) 34%, 50%, 75% vs. (R) 22%, 56%, 80%

Reference	Manipulation (no. of patients)	Reference Treatment (no. of patients)	Results
Blomberg ¹⁷⁻¹⁹	(I) SI-joint mobilization and thrust techniques (48)	(R) Active, optimal conventional physiotherapeutic treatment (53)	Mean pain score (VAS) after 1, 2, and 4 mo: (I) 13.7, 11.4, 8.5; (R) 23.9, 19.3, 20.9. (I) significantly better; average no. of days on sick-leave during 8-mo-follow-up: (I) 25.4, (R) 58.5
Rasmussen ¹²⁸	(I) Rotational (12)	(R) Shortwave diathermy (12)	Percentage of patients with total recovery after 2 wk 92% (I) vs. 25% (R); manipulation significantly better
Delitto ³²	(I) Mobilization SI-joint (14)	(R) Flexion exercises (10)	Group (I) significantly more improved in functional status (Oswestry) after 3 and 5 days vs. group (R)
Farrell ⁴⁵	(I) Stoddard, Maitland (24)	(R) Shortwave diathermy and exercises (24)	Group (I) symptom-free in significantly less days than group (R)
Nwuga ¹²¹	(I) Rotational (26)	(R) Shortwave diathermy and exercises (25)	Improvement after 6 wk in spinal flexion 34° (I) vs. 13° (R) and in SLR 39° (I) vs. 4° (R); group (I) significantly better than group (R)
Waterworth ¹⁵⁶	(I) At discretion of therapist (38)	(R1) Shortwave diathermy, ultrasound, and exercises (34) (R2) NSAIDs (36)	Mean change in pain intensity on 4-point scale after 4 and 12 days: (I) -1.1, -1.7, (R1) -0.9, -1.6, (R2) -0.9, -1.7; no significant differences in pain intensity and mobility
Postacchini ¹²⁷	(I) Chiropractic manipulation (35)	(R1) Physiotherapy (31) (R2) NSAIDs (34) (R3) Bed rest (29) (R4) Placebo: anti-edema gel (30)	Mean improvement on combined pain, disability, and spinal mobility score after 3 wk 7.5 (I), 5.0 (R1), 3.0 (R2), and 5.4 (R3), 1.8 (R4), after 2 mo 9.7 (I), 8.4 (R1), 10.7 (R2), 7.5 (R3), 7.3 (R4) and after 6 mo 12.3 (I), 10.2 (R1), 14.0 (R2), 7.3 (R3), 11.0 (R4); manipulation significantly better after 3 wk
Wreje ¹⁶³	(I) SI-joint mobilization (18)	(R) Massage (21)	Pain (VAS) after 3 wk not different (data in graphs); sick-leave and analgesic consumption significantly less in (I) than (R)
Godfrey ⁵¹	(I) Rotational (44)	(R) Massage and electrical stimulation (37)	Percentage of patients with moderate/marked improvement on general symptomatology on a 5-point scale after 2 wk 77% (I) vs. 70% (R); no significant differences on other outcome measures

NSAIDs = nonsteroidal anti-inflammatory drugs; SLR = straight leg raising.

Table 14. Details of Randomized Controlled Trials on the Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Low Back Pain

Reference	TENS/Acupuncture (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Herman ⁶³	(I) Rehabilitation program (4 hr per day, 5 days/wk, 4 wk) plus TENS (15 min high frequency, 15 min low frequency, 5 days/wk, 4 wk) (29)	(R) Rehabilitation program plus placebo TENS (29)	Mean (SD) scores pretreatment and posttreatment of functional status (RDQ) (I) 12.5 (5.1), 8.9 (5.0) vs. (R) 14.3 (5.2), 9.9 (6.4), pain (100 mm VAS) (I) 42.7 (23.3), 35.8 (27.7) vs. (R) 47.9 (21.3), 35.9 (27.0) and lumbar flexion (Schober test mm) (I) 50.9 (16.2), 60.2 (10.5) vs. (R) 44.8 (15.9), 61.7 (13.9); not significant
Hackett ⁵⁶	(I) TENS low amplitude, 15 min, 2 treatments, 4 days (-)	(R) Paracetamol 2 tablets every 4 hr (-)	Scores for pain (VAS) pretreatment and after 6 wk (I) 52.7, 3.3 vs. (R) 54.4, 13.7; significant after 6 wk, but not after 1 and 2 wk; scores for mobility (VAS) pretreatment and after 6 wk (I) 53.4, 1.9 vs. (R) 51.2, 15.8; significant after 6 wk, but not after 1 and 2 wk

TENS = transcutaneous electrical nerve stimulation.

Table 15. Details of Trials on the Efficacy of Traction for Acute Low Back Pain

Reference	Traction (no. of patients)	Reference Treatment (no. of patients)	Results
Larson ⁸⁹	(I) Autotraction plus corset plus bed rest, 1 hr, 1-3 treatments, 1 wk (41)	(R) Corset plus bed rest (41)	No. of patients improved after 1 wk, 3 wk, and 3 mo (I) 17/41, 20/41, 19/41, (R) 2/41, 8/41, 17/41; (I) significantly better after 1 and 3 wk
Mathews ¹⁰⁵	(I) Continuous motorized traction >45 kg, 30 min, 5 days per week, max 3 wk (83)	(R) Infrared heat 15 min, 3 times per week, 2-3 wk (60)	Recovery after 2 wk (I) 40/77, (R) 27/54; not significant

Table 16. Details of Trials on the Efficacy of Behavioral Therapy for Acute Low Back Pain

Reference	Behavioral Therapy (no. of patients)	Reference Treatment (no. of patients)	Results
Fordyce ⁴⁶	(I) Behavioral management; analgesics and exercise continued on a fixed time interval (57)	(R) Traditional management: analgesics and exercise until pain had subsided (50)	Mean (SD) score on pain drawings and claimed impairment after 9–12 mo (I) 1.98 (2.46), 4.84 (3.20) vs. (R) 3.06 (2.45), 6.25 (3.25); (I) significantly better than (R) after 9–12 mo on pain drawings and claimed impairment; no significant differences after 6 wk

Table 17. Details of Randomized Controlled Trials on the Effectiveness of Various Drug Therapies for Chronic Low Back Pain

Reference	Dose/Frequency/Duration (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Analgesics Hickey ⁶⁵	(I) Paracetamol 1000 mg qid/4 wk (13)	(R) Diflunisal 500 mg bid/4 wk (16)	No. of patients with none or mild LBP after 2 and 4 wk (I) 9, 7 (R) 11, 13; significantly more patients in (R) 10 of 16 considered the therapy as good or excellent vs. (I) 4 of 12; side effects comparable (I) 1 and (R) 2
Muscle relaxants Arbus ⁶	(I) Tetrazepam 50 mg tid/10 days (25)	(R) Placebo tid/10 days (25)	Overall efficacy significantly better in (I) 64% than in (R) 29%; mean (SD) pain score (5-point scale) at baseline and after 4 and 10 days in (I) 3.40 (0.82), 2.50 (0.94), and 1.73 (1.31) vs. (R) 3.36 (0.62), 3.10 (0.71), and 2.38 (1.08); (I) significantly more improved; no difference in side effects
Antidepressants Goodkin ⁵⁴	(I) Trazodone 50 mg/1 tabl initially to maximum 12 tabl per day/6 wk (22)	(R) Placebo (20)	Mean (SD) pain score (VAS) pre- and posttreatment (I) 6.5, 5.3 vs. (R) 6.5, 5.9; physical functioning (SIP) (I) 26.7, 24.4 vs. (R) 27.7, 22.8; psychosocial functioning (SIP) (I) 28.5, 29.0 vs. (R) 27.0, 20.8; depression (BDI) (I) 16.3, 14.1 vs. (R) 15.2, 11.8; pain and depression not significantly different, placebo significantly better physical and psychosocial functioning (I) significantly better than (R) in decreasing limitation of physical functioning, no significant difference in pain severity or depression; no means and SDs presented for any outcome measure
Alcoff ³	(I) Imipramine 75 mg/1–2 tabl per day/8 wk (28)	(R) Placebo (22)	(I) significantly better than (R) in decreasing limitation of physical functioning, no significant difference in pain severity or depression; no means and SDs presented for any outcome measure
Jenkins ⁷¹	(I) Imipramine 25 mg/3 tid/4 wk (23)	(R) Placebo (21)	No differences between (I) and (R) on improvement of pain, depression, and spinal mobility from pre- to posttreatment; data in graphs; in the 15 most depressed patients depression decreased in (I) 6 of 8 subjects vs. (R) 3 of 7 subjects; not significant
Pheasant ¹²⁶	(I) Amitriptyline 50 mg/1–3 tabl per day/6 wk (9)	(R) Placebo: atropine 0.2 mg/1–3 tabl per day/6 wk (9)	Crossover design; change in functional evaluation (I) 0.00, (R) –0.06; not significant; mean no. (SD) of analgesics per week (I) 4.7 (3.4) vs. (R) 8.7 (4.8); significant
NSAIDs Hickey ⁶⁵	(I) Diflunisal 500 mg bid/4 wk (16)	(R) Paracetamol 1000 mg qid/4 wk (13)	No. of patients with none or mild LBP after 2 and 4 wk (I) 11, 13 (R) 9, 7; significantly more patients in (I) 10 of 16 considered the therapy as good or excellent vs. (R) 4 of 12; side effects comparable (I) 2 and (R) 1
Siegmeth ¹³⁸	(I1) Ibuprofen/1200 mg day/14 days (15) (I2) Diclofenac/75 mg day/14 days (15)		No. of patients reporting to be improved after 1, 3, and 4 wk (I1) 5, 10, 6 (I2) 5, 12, 11; no significant differences; side effects comparable; one in each group
Videman ¹⁵³	(I1) Piroxicam 20 mg day/6 wk (14) (I2) Indomethacin 25 mg tid/6 wk (14)		Mean improvement on VAS (range 0–31) after 6 wk (I1) 8 vs. (I2) 9; similar improvement rates (data in graphs); comparable side effects (I1) 13 vs. (I2) 15
Berry ¹²	(I1) Naproxen sodium 550 mg bid/14 days (37) (I2) Diflunisal 500 mg bid/14 days (37)	(R) Placebo (37)	Crossover design: (I1) reduction of pain (VAS) (I2) no change (R) increase of pain (data in graphs); (I1) significantly better than (R) and somewhat better than (I2); side effects comparable in the three groups (I1) 18, (I2) 18, (R) 16

Reference	Dose/Frequency/Duration (no. of patients)	Reference Treatment(s) (no. of patients)	Results
Matsumo ¹⁰⁸	(I1) Ketoprofen 150 mg day/duration not given (77) (I2) Diclofenac 75 mg day/duration not given (78)		Patients improved after 1 and 2 wk (I1) 71%, 86%, (I2) 62%, 79%; no significant differences; side effects comparable in both groups: (I1) 18%, (I2) 21%
Postacchini ¹²⁷	(I) Diclofenac "full dosage" 15–20 days (81)	(R1) Manipulation (87) (R2) Physiotherapy (78) (R3) Back school (50) (R4) Antiedema gel (73)	Mean improvement on combined pain, disability, and spinal mobility score after 3 wk, 2 and 6 mo in subgroup with chronic pain (I) 2.6, 2.2, 4.0, (R1) 2.2, 2.6, 4.3, (R2) 3.9, 4.2, 6.0, (R3) 0.5, 4.6, 8.9, (R4) 0.7, 1.2, 2.0; group (I) not significantly better; no data on side effects reported

NSAIDs = nonsteroidal anti-inflammatory drugs; tabl = tablets; bid = twice per day; tid = three times per day.

Table 18. Details of Randomized Controlled Trials on the Effectiveness of Epidural Steroid Injections for Chronic Low Back Pain

Reference	Epidural Steroid Injection, Route (no. of patients)	Reference Treatment (no. of patients)	Results
Breivik ²²	(I) Methylprednisolone 80 mg (2 ml) + 20 ml bupivacaine 0.25%, caudal route, 1–3 injections (16)	(R) Bupivacaine 20 ml 0.25% + 100 ml saline (19)	Percentage of patients with considerable pain relief and objective neurological improvement (before crossover) (I) (56% (R) (26%; significant
Bush ²⁵	(I) Triamcinolone 80 mg + 25 ml procaine 0.5%, caudal route, 2 injections (12)	(R) Saline 25 ml (11)	Mean VAS (100 mm) of back and leg pain at baseline, 4 and 52 wk (I) 39, 16, 14 (R) 49, 45, 30; mean straight leg raising (SLR, °) at baseline, 4 and 52 wk (I) 44, 73, 80 (R) 63, 65, 74; short-term (I) significantly better results on pain and SLR; long-term (I) significantly better SLR
Cuckler ²⁹	(I) Methylprednisolone 80 mg (2 ml) + 5 ml procaine 1%, lumbar route, 1–2 injections (42)	(R) Saline 2 ml + 5 ml procaine 1% (31)	Average subjective improvement after 24 hr (I) 42% (R) 44%; not significant; long-term follow-up (about 20 mo) showed no significant differences
Serrao ¹³⁷	(I) Prednisolone 80 mg + 10 ml saline (epidural) + 3 ml dextrose (intrathecal), lumbar route, 1 injection (14)	(R) Saline 10 ml (epidural) + 2 mg midazolam + 3 ml dextrose 5% (intrathecal) (14)	No. of patients reporting overall improvement initially and after 2 mo (I) 3, 5 (R) 10, 7; (R) significantly better short-term improvement; no significant differences for pain and activity scores; (R) significantly less self-administered medications
Rocco ¹³¹	(I1) Triamcinolone 75 mg (10.9 ml) + 50 mg lignocaine, lumbar route (8), 1–3 injections; (I2) Triamcinolone 75 mg + 50 mg lignocaine + 8 mg morphine (10.9 ml), 1–3 injections (7)	(R) Lignocaine 50 mg + 8 mg morphine (10.9 ml) (7)	Mean improvement on pain (VAS) after 1 and 6 mo (I1) 0.9, 2.2 (I2) –0.6, –1.7 (R) 0.4, –0.8; no. of patients reporting pain relief after 1 and 6 mo (I1) 5, 1, (I2) 6, 0, (R) 7, 0; no significant differences
Ridley ¹²⁹	(I) Methylprednisolone 80 mg + 10 ml saline, lumbar route (19)	(R) Saline 2 ml, interspinous ligament (16)	Percentage of patients improved after 2 wk (I) 90%, (R) 19%; short-term (I) significantly better than (R) in relieving pain

Table 19. Details of Randomized Controlled Trials on the Effectiveness of Manipulation for Chronic Low Back Pain

Reference	Manipulation (no. of patients)	Reference Treatment (no. of patients)	Results
Koes ^{80–83}	(I) Spinal manipulation and mobilization (65)	(R1) Physiotherapy (66) (R2) Usual care by GP (61) (R3) Detuned shortwave diathermy and detuned ultrasound (64)	No differences on pain and functional status; mean improvement for main complaint (10-point scale) after 3 wk (I) 2.3, (R1) 2.0, (R2) 1.3, (R3) 1.7, after 6 wk (I) 3.4, (R1) 3.4, (R2) 2.0, (R3) 2.7, after 12 wk (I) 4.0, (R1) 3.8, (R2) 3.9, (R3) 3.8; global perceived effect (6-point scale) after 3 wk (I) 2.5, (R1) 2.6, (R2) 1.6, (R3) 2.1, after 6 wk (I) 3.4, (R1) 3.3, (R2) 1.9, (R3) 2.8, after 12 wk (I) 3.4, (R1) 3.7, (R2) 2.2, (R3) 3.3; group (I) and (R1) significantly better than group (R2), no differences between group (I) and (R1); (I) significantly better global perceived effect than (R3)
Ongley ¹²⁴	(I) Bourdillon (40)	(R) Nonforceful manipulation (41)	Mean (SEM) pain score (VAS) after 1, 3, and 6 mo: (I) 2.1 (0.2), 1.8 (0.2), 1.5 (0.2) vs. (R) 3.1 (0.3), 2.9 (0.3) and 3.1 (0.3); all differences significant

Reference	Manipulation (no. of patients)	Reference Treatment (no. of patients)	Results
Triano ¹⁴⁶	(I) High velocity low amplitude (?)	(R1) Back education (46) (R2) High velocity low force mimic (?)	Mean pain score (VAS) at baseline, after 2 wk and 2 wk after treatment (I) 38.4, 13.9, and 13.3 and (R1) 35.6, 19.6, and 15.1, (R2) 37.4, 19.8, 21.7, respectively; (I) significantly more improved on pain score after 2 wk than (R1); mean functional status score (Oswestry) at baseline, after 2 wk and 2 wk after treatment (I) 17.5, 9.5, and 10.6 and (R1) 20.2, 12.3, and 11.4, (R2) 21.7, 15.5, 14.0, respectively; no significant differences
Gibson ⁴⁸	(I) Osteopathic (41)	(R1) Shortwave diathermy (34) (R2) Detuned shortwave diathermy (34)	Percentage of patients free of pain after 4 wk (I) 28%, (R1) 28%, (R2) 42% and after 12 wk (I) 42%, (R1) 37%, (R2) 44%; not significant; median pain scores (VAS) at baseline and after 2, 4, and 12 wk (I) 35, 25, 21, 13, (R1) 45, 35, 28, 25, (R2) 48, 28, 27, 6; not significant
Herzog ⁶⁴	(I) Chiropractic (16)	(R) Back school (13)	Group (R) significantly better improvement no pain, functional status (Oswestry) than (I), (I) significantly better on gait symmetry than (R)
Evans ¹¹	(I) Rotational (15)	(R) Analgesics (17)	No. of patients assessing treatment as effective after 3 wk 9 (I) vs. 3 (R); significant
Waagen ¹⁵⁵	(I) Chiropractic (9)	(R) Massage and sham manipulation (10)	Group (I) significantly better improvement on 10 cm VAS after 2 wk: 2.3 (I) vs. 0.6 (R)
Arkuszewski ⁷	(I) Lewit (50)	(R) Bed rest, analgesics, and massage (50)	Mean (SD) pain intensity (4-point scale) posttreatment and after 6 mo (I) 0.6 (0.5), 0.7 (0.6) vs. (R) 1.0 (0.4), 1.0 (0.5); (I) significantly more improved
Postacchini ¹²⁷	(I) Chiropractic manipulation (87)	(R1) Physiotherapy: light massage, analgesic currents, and diathermy, daily for 3 wk (78) (R2) Diclofenac "full dosage," 15–20 days (81) (R3) Low back school (50) (R4) Antiedema gel (73)	Mean improvement on combined pain, disability, and spinal mobility score after 3 wk, 2 and 6 mo in subgroup with chronic pain (I) 2.2, 2.6, 4.3, (R1) 3.9, 4.2, 6.0, (R2) 2.6, 2.2, 4.0, (R3) 0.5, 4.6, 8.9, (R4) 0.7, 1.2, 2.0; (I) not significantly better

Table 20. Details of Randomized Controlled Trials on the Effectiveness of Back Schools for Chronic Low Back Pain

Reference	Back School (no. of patients)	Reference Treatment (no. of patients)	Results
Harkapaa ^{59,60,110,111}	(I1) Inpatient group: 3-wk rehabilitation period in groups of 6–8 patients: modified Swedish back school (4 sessions), 15 sessions back exercises, 9 sessions relaxation exercises, supervised by physiotherapist; heat or electrotherapy and massage and session with physiologist and physician; refresher course 2 wk after 1.5 yr (156) (I2) Outpatient group: 15 sessions during a 2-mo period, twice a week in groups of 6–8 patients: modified Swedish back school (4 sessions), 15 sessions back exercises, 9 sessions relaxation exercises, supervised by physiotherapist and session with physiologist and physician; refresher course 8 sessions after 1.5 yr (150)	(R) no systematic treatment; written and oral instructions on back exercises and ergonomics (153)	Changes in pain index and disability index after 3 mo follow-up: significantly greater reduction in (I1) and (I2) than in (R) (data in graphs and by ANOVA); at 2.5 yr follow-up no clear differences

Reference	Back School (no. of patients)	Reference Treatment (no. of patients)	Results
Hurri ^{69,70,73}	(I) Modified Swedish back school: 60 min education and exercise session, 6 times in 3 wk; refresher course 2 × 60 min after 6 mo; supervised by physiotherapist; 11 patients per group (95)	(R) Instruction material of the back school in written form; no actual treatment, but free to use health care services (93)	VAS, Pain Index, and Oswestry's Index after 6 mo follow-up (I) significantly better than (R); after 12 mo no differences (data in graphs)
Linton ⁹⁶	(I) 5-wk period in a back clinic; 8 hr/day mostly in groups of 6 patients; exercise activities (walking, swimming, jogging, cycling) 4 hr/day; ergonomic education, individual physical therapy programs, behavior therapy techniques (36)	(R) Waiting list control: no additional active treatment (30)	Pain intensity (VAS) significantly better in (I) than (R) after 6 wk and 6 mo (data in graphs and by ANCOVA for repeated measures); other outcome measures (fatigue, anxiety, sleep quality) similar results
Lankhorst ⁸⁸	(I) Swedish back school: 4 sessions of 45 min in the course of 2 wk (anatomy and causes of LBP, function muscles and posture, ergonomics, advice on physical activity) (21)	(R) 4 sessions with detuned shortwave applications in a period of 2 wk (22)	Mean pain on 10-point scale after the intervention and after 3, 6, and 12 mo; (I) 6.0, 5.9, 6.2, 5.6 (R) 6.8, 6.5, 5.8, 6.5; no significant differences (including functional capacity)
Keijsers ⁷⁵	(I) Maastricht back school: education and skills program in group setting (10–12 patients): 7 lessons of 2.5 hr, refresher lesson after 6 mo; including postural education, exercises, information on psychological factors (—)	(R) Waiting list control group (—)	Mean pain (VAS) after 2 and 6 mo (I) 5.4, 5.4 vs. (R) 5.2, 4.6; no significant differences including functional status
Donchin ³⁷	(I) 4 90 min sessions during a 2-wk period plus a fifth session after 2 mo; 10–12 patients per group supervised by a physiotherapist (education and exercises for back and abdominal muscles) (46)	(R1) Calisthenics in 45 min sessions biweekly for 3 mo in groups of 10–12 patients (flexion and strengthening exercises) (46) (R2) Control group (were promised the most effective program in the future) (50)	Incidence of LBP episodes (mean of painful months during 12 mo follow-up): (I) 7.3 (R1) 4.5 (R2) 7.4; (R1) significantly better than (I) and (R2)
Postacchini ¹²⁷	(I) Based on Canadian Back Education Unit: four 1-hr sessions in a 1-wk period (including muscle exercises) (50)	(R1) Manipulation daily first week, then twice a week for 6 wk (52) (R2) NSAIDs (15–20 days) (47) (R3) Physiotherapy: light massage, analgesic current, and diathermy daily for 3 wk (47) (R4) Antiedema gel twice a day for 2 wk (43)	Mean improvement on combined pain, disability, and spinal mobility scores after 3 wk, 2 mo, and 6 mo; (I) 0.5, 4.6, 8.9 (R1) 2.2, 2.6, 4.3 (R2) 2.6, 2.2, 4.0 (R3) 3.9, 4.2, 6.0 (R4) 0.7, 1.2, 2.0; back school significantly better after 2 and 6 mo
Herzog ⁶⁴	(I) Back school program (including instruction on how to move and stretching postural exercises) supervised by physiotherapist: 10 sessions in a 4-wk period (13)	(R) Manipulation: 10 treatment sessions in 4 wk (16)	Mean pain score after 4 wk significantly lower in (I) vs. (R) (data in graphs); (R) significantly better in restoring gait symmetry
Klaber ⁷⁷	(I) Swedish back school: 3 sessions containing education on anatomy and body mechanics, semi-Fowler position, ergonomic counseling, and exercises aiming at strengthening the abdominal muscles (40)	(R) Exercises only [same as in group (I)] (38)	Change in mean pain and functional disability scores after 8 and 16 wk significantly larger in (I) vs. (R) (data in graphs)
Keijsers ⁷⁴	(I) Maastricht back school: education and skills program in group setting (10–12 patients): 7 lessons of 2.5 hr and refresher lesson after 8 wk; including postural education, exercises, information on psychological factors (20)	(R) Waiting list control group (20)	VAS for pain after the program: (I) 28.9 (R) 31.9; no significant differences for most of the outcome measures, including daily activities

NSAIDs = nonsteroidal anti-inflammatory drugs.

Table 21. Details of Randomized Controlled Trials on the Effectiveness of Electromyogram (EMG) Biofeedback Therapy for Chronic Low Back Pain

Reference	Index Treatment (no. of patients)	Reference Treatment (no. of patients)	Results
Asfour ⁸	(I) Rehabilitation program + progressive extension training in lying position with auditory and visual EMG biofeedback (8 sessions) (15)	(R) Rehabilitation program (15)	Mean (SD) pain intensity pretreatment and post-treatment (2 wk) (I) 6.1 (2.9), 4.7 (2.6) (R) 5.6 (2.4), 5.6 (2.4); not significant; ROM not different between groups; (I) significantly more increase in strength

Reference	Index Treatment (no. of patients)	Reference Treatment (no. of patients)	Results
Bush ²⁴	(I) Auditory EMG biofeedback training in sitting position until decrease and increase of 2 μ V without feedback was reached with max 8 sessions (22)	(R1) Placebo feedback of back temperature (22) (R2) Waiting list control (22)	No significant differences in pain intensity, functional status, or psychosocial status
Nouwen ¹²⁰	(I) Auditory and visual EMG biofeedback training in standing position, 15 sessions in 3 wk (10)	(R) Waiting list control, no treatment (10)	Mean (SD) pain level (duration $\times$ intensity) pre- and posttreatment (I) 15.8 (9.4), 14.3 (8.6) vs. (R) 18.4 (11.8), 19.1 (15.6); not significant
Stuckey ¹⁴²	(I) Relaxation training: progressive relaxation, breathing techniques, autogenic training, visual imagery; 8 sessions of 45 min (8)	(R1) EMG biofeedback training; 8 sessions of 45 min (8) (R2) Placebo EMG: no feedback, no relaxation instructions; 8 sessions of 45 min (8)	Mean scores of pain intensity during function test (range 0–100) at first and last treatment session (I) 36.8, 28.0, (R1) 26.2, 31.6, (R2) 42.4, 44.4 and ADL (range 1–7) (I) 2.4, 2.9, (R1) 2.6, 2.5, (R2) 2.2, 2.4; (I) significantly more improved on pain intensity than (R1) and (R2), and significantly more improved on ADL than (R1)
Donaldson ³⁶	(I) Progressive relaxation training (Lehrer & Woolfolk), 10 35-min sessions (12)	(R1) Single motor unit biofeedback training (Johnson, Mulder), 10 35-min sessions (12) (R2) Education on anatomy, exercise, depression, stress; 10 35-min sessions (12)	Mean scores on McGill Pain Questionnaire (MPQ) and pain intensity (VAS) pretreatment (I) 31.08, 2.51, (R1) 28.75, 2.23, (R2) 34.50, 3.48, posttreatment (I) 27.67, 1.90, (R1) 16.08, 1.26, (R2) 28.58 2.47 and after 3 mo (I) 32.33, 1.78, (R1) 15.33, 0.72, (R2) 20.08, 0.87; (R1) significantly more improved after 3 mo than (I); no significant differences on pain intensity between groups

ROM = range of motion; ADL = activities of daily living.

Table 22. Details of Randomized Controlled Trials on the Effectiveness of Exercise Therapy for Chronic Low Back Pain

Reference	Exercise Regimen (no. of patients)	Reference Treatment (no. of patients)	Results
Deyo ³⁴	(I1) Stretching exercises and TENS (34) (I2) Stretching exercises and sham TENS (29)	(R1) TENS (31) (R2) Sham TENS (31)	Mean improvement pain (VAS 0–100%) and activity (VAS 0–100%) after 4 and 12 wk; (I1) and (I2) 52%, 48%, (R1) and (R2) 37%, 41%; exercise significantly better
Hansen ⁵⁸	(I) Intensive dynamic back muscle training (60)	(R1) Physical therapy: manual traction, hot packs, massage and flexibility, coordination and slowly progressive back and abdominal muscle exercises (59) (R2) Placebo control: semihot packs and light traction (61)	No significant differences in pain level (10-point scale) between groups posttreatment and after 1, 6, and 12 mo; overall treatment effect (10-point scale) of (I) and (R1) significantly higher at all evaluations than (R2); no significant changes over time
Manniche ^{100,101}	(I1) Intensive back extensor (27) (I2) Mild isometric exercises/massage/hot compress (32) (I3) Mild back extensor (31)		Median improvement in combined pain, disability, physical impairment index (0–100 points) after 3 and 9 mo; (I1) 14.7, 15.0, (I2) 2.0, 5.5, (I3) 5.7, 7.0; (I1) significantly better than (I2) and (I3)
Elnaggar ³⁹	(I1) McKenzie extension (28) (I2) Williams flexion (28)		Mean (SD) scores on McGill Pain Questionnaire (range 0–78) pretreatment and posttreatment: (I1) 15.9 (7.8) and 10.6 (8.6) vs. (I2) 14.1 (9.8) and 8.9 (9.4); no significant difference
Lidström ⁹²	(I1) Isometric strengthening and pelvic traction (20) (I2) Mobilizing/strengthening, hot packs, and massage (21)	(R) Hot packs and rest (21)	No. of patients with noticeable improvement after 4 wk; (I1) 17, (I2) 9 and (R) 12; patients in (I1) significantly better than (I2) and (R)
Manniche ¹⁰²	(I1) Intensive dynamic exercises plus hyperextension (31) (I2) Intensive dynamic exercises (31)		Overall improvement posttreatment and after 3 and 12 mo not significantly different in (I1) and (I2); improvement on low back pain rating scale (0–100) posttreatment and after 3 and 12 mo in (I1) 10, 8, 3 vs. (I2) 7, 1, 0; significant at 3 mo
Lidström ^{94,95}	(I) Individual, submaximal, gradually increased exercise program: endurance and strength training, lifting, walking, jogging, swimming, fitness (51)	(R) Traditional care (52)	Proportion of patients returned to work within 6 wk or 12 wk after randomization: (I) 59%, 80% vs. (R) 40%, 58%; significant; mean (SD) duration of sick-leave due to LBP during second follow-up year: (I) 12.1 (18.4) wk vs. (R) 19.6 (20.7) wk; significant; no differences in functional status (whole body mobility) after 1 yr

Reference	Exercise Regimen (no. of patients)	Reference Treatment (no. of patients)	Results
Johanssen ⁷²	(I1) Dynamic back, neck, abdominal endurance exercises/stretching (20) (I2) Coordination/balance exercises (20)		Median pain score (scale 0–8) pretreatment and after 3 and 6 mo (I1) 6, 3, 4 vs. (I2) 6, 5, 4; not significant; median disability score (scale 0–12) (I1) 6, 2, 1 vs. (I2) 5, 3, 2; not significant
Turner ¹⁵¹	(I1) Aerobic exercises (24) (I2) Aerobic exercises and operant conditioning behavioral therapy (24)	(R1) Operant conditioning behavioral therapy (25) (R2) Waiting list control group (23)	Mean scores on McGill Pain Questionnaire and SIP pretreatment (I1) 19.42, 8.42, (I2) 25.54, 8.50, (R1) 20.96, 7.90 and (R2) 21.17, 6.24 and post-treatment (I1) 17.52, 5.49, (I2) 12.41, 4.59, (R1) 17.71, 4.72 and (R2) 20.95, 5.37; (I2) significantly more improved than (I1) and (R2); no significant differences between (I1), (I2) and (R1) after 6 and 12 mo
Kendall ⁷⁶	(I1) Isometric flexion (14) (I2) Mobilization (14) (I3) Extension (14)		No. of patients symptom-free or improved after 1 and 3 mo (I1) 13, 11, (I2) 11, 8, (I3) 7, 6; (I1) significantly better than (I2) and (I3)
Risch ¹³⁰	(I) Dynamic extension exercise program (31)	(R) Waiting list control group (23)	Mean (SD) pain score pre- and posttreatment (I) 3.4 (1.6), 2.9 (1.7) vs. (R) 3.7 (1.6), 4.1 (1.5); significant; mean (SD) physical disability score (SIP) (I) 9.1 (9.3), 7.7 (9.4) vs. (R) 15.2 (10.4), 19.3 (15.6); significant
Martin ¹⁰⁴	(I1) Mobilizing abdominal and back muscles (12) (I2) Isometric abdominal and pelvic floor muscles (12)	(R) Detuned ultrasound and detuned shortwave diathermy (12)	Change in pain intensity (5-point scale) after 5 wk; (I1) decrease, (I2) increase, (R) decrease; no significant differences in physiological and clinical measures
Buswell ²⁶	(I1) Flexion program (25) (I2) Extension program (25)		Similar improvement of pain and function after treatment for (I1) and (I2); data not given
Sachs ¹³⁴	(I1) Rehabilitation program: stretching/strengthening/cardiovascular conditioning exercises plus exercises on B-200 isostation (14)	(R) Rehabilitation program (16)	No significant difference in range of motion after 3 wk treatment period
Frost ⁴⁷	(I) Fitness program and back school education (36)	(R) Back school education (35)	Mean (SD) scores on functional status (Oswestry) and pain (0–100 scale) pretreatment (I) 23.6 (9.7), 20.9 (12.3) vs. (R) 23.6 (12.3), 25.6 (17.9) and post-treatment (I) 17.6 (10.9), 12.1 (9.9) vs. (R) 21.7 (13.6), 22.1 (20.1); (I) significantly more improved than (R); after 6 mo (I) significantly more improved functional status than (R)
White ¹⁵⁹	(I1) Mild static trunk and shortwave diathermy (76) (I2) Vigorous flexion and extension (72)		Proportion of patients showing improvement after treatment (max 7 wk) 38% (I1) vs. 35% (I2); not significant

TENS = transcutaneous electrical nerve stimulation.

Table 23. Details of Randomized Controlled Trials on the Effectiveness of Traction and Orthoses for Chronic Low Back Pain

Reference	Index Treatment (no. of patients)	Reference Treatment (no. of patients)	Results
Traction Heijden ⁶¹	(I) Continuous motorized traction, 30–50% of body weight, 20 min, 3 times per week, 4 wk (13)	(R) Continuous motorized traction, 0–25% of body weight, 20 min, 3 times per week, 4 wk (12)	Median improvement of pain and functional status after 5 wk (I) 14, 2 vs. (R) 16, 1 and after 9 wk (I) 14, 2 vs. (R) 4, 2; no. of patients completely recovered or much improved after 5 and 9 wk in (I) 7/13, 5/13 vs. (R) 4/12, 3/12; no significant differences
Orthoses Million ¹¹⁵	(I) Corset with lumbar support for 8 wk (9)	(R) Corset without lumbar support for 8 wk (10)	Overall subjective improvement index: (I) highly significant improvement (R) no change; overall objective improvement index: (I) and (R) improvement over the study period but no difference between groups

Table 24. Details of Randomized Controlled Trials on the Effectiveness of Behavior Therapy for Chronic Low Back Pain

Reference	Index Treatment (no. of patients)	Reference Treatment (no. of patients)	Results
Lindström ^{94,95}	(I) Individual, submaximal, gradually increased exercise program with an operant conditioning behavioral approach (Fordyce) (51)	(R) Traditional care (52)	Proportion of patients returned to work within 6 wk or 12 wk after randomization: (I) 59%, 80% vs. (R) 40%, 58%; significant; mean (SD) duration of sick-leave due to LBP during the second follow-up year: (I) 12.1 (18.4) wk vs. (R) 19.6 (20.7) wk; no differences in functional status after 1 yr

Reference	Index Treatment (no. of patients)	Reference Treatment (no. of patients)	Results
Turner ¹⁵⁰	(I1) Aerobic exercises and operant conditioning (Fordyce); 2 hr/wk, 8 wk (30) (I2) Cognitive behavioral approach; systematic progressive muscle relaxation (Bernstein & Borkovec) and imagery; 2 hr/wk, 8 wk (26)	(R) Waiting list control group (25)	Mean (SD) scores on McGill Pain Questionnaire and SIP pretreatment, posttreatment, and after 6 and 12 mo; (I1) 23.07 (12.37), 18.50 (12.43), 19.57 (15.31), 15.07 (11.62) vs. (I2) 18.30 (10.43), 15.92 (11.63), 12.70 (12.75), 10.80 (6.38); not significant; (I1) significantly better posttreatment than (R) on pain and physical and psychosocial functioning
Nicholas ¹¹⁹	(I) Cognitive behavioral approach, including progressive muscle relaxation training (Bernstein & Borkovec), and physiotherapy; one 2 hr and one 1.5 hr session/wk, 5 wk (10)	(R) Physiotherapy: information, exercises, and handouts (one 2 hr and one 1.5 hr session/wk/5 wk) and attention (5 sessions) (10)	Mean (SD) scores of pain intensity (6-point nominal scale) and functional status (SIP) pretreatment, posttreatment, and after 6 mo; (I) 3.13 (0.88), 3.07 (0.79), 2.89 (0.64) and 30.87 (12.17), 18.81 (10.97), 18.30 (11.18) vs. (R) 2.84 (0.85), 2.72 (0.77), 2.75 (1.11) and 32.10 (13.45), 26.08 (16.40), 25.31 (14.34); not significant; (I) significantly better posttreatment than (R) on coping strategies, pain self-efficacy, and medication use; after 6 mo (I) significantly better coping strategies
Nicholas ¹¹⁸	(I1) Behavioral treatment (operant conditioning Fordyce) and physiotherapy; one 2 hr and one 1.5 hr session/wk/5 wk (10) (I2) Behavioral treatment and physiotherapy and progressive muscle relaxation training; one 2 hr and one 1.5 hr session/wk/5 wk (9) (I3) Cognitive treatment (coping strategies) and physiotherapy; one 2 hr and one 1.5 hr session/wk/5 wk (10) (I4) Cognitive treatment and physiotherapy and progressive muscle relaxation training; one 2 hr and one 1.5 hr session/wk/5 wk (8)	(R1) Physiotherapy: information, exercises and handouts (one 2 hr and one 1.5 hr session/wk/5 wk) (11) (R2) Physiotherapy (one 2 hr and one 1.5 hr session/wk/5 wk) and attention (5 sessions) (10)	Posttreatment (I1), (I2), (I3) and (I4) significantly more improved on pain intensity (6-point nominal scale), self-rated functional impairment (SIP), and pain beliefs than (R1) and (R2), but no significant differences after 6 and 12 mo; (I1) and (I2) significantly more improved posttreatment on self-rated SIP than (I3) and (I4); no other differences between index treatments after 6 and 12 mo on any of the outcome measures
Turner ¹⁴⁷	(I1) Progressive muscle relaxation training (Bernstein & Borkovec) (14 posttreatment; 18 follow-up) (I2) Cognitive behavioral therapy: relaxation, coping, imagery (13 posttreatment; 16 follow-up)	(R) Waiting list control group (9)	Mean (SD) score on self-rated functional impairment (SIP) and pain (VAS) pretreatment (I1) 14.6 (8.2), 57.9 (21.6), (I2) 18.6 (7.9), 55.2 (24.8), (R) 20.2 (11.1), 54.0 (32.0) and posttreatment (I1) 9.1 (8.3), 42.3 (20.2), (I2) 10.2 (6.9), 36.5 (22.7) and (R) 20.2 (8.2), 77.0 (21.6); (I1) and (I2) significantly better posttreatment than (R); pain score (I1) after 1 mo significantly better than (I2), no other differences between (I1) and (I2) posttreatment, after 1 mo and 1.5 yr on pain, depression, and functional status
Turner ¹⁴⁹	(I1) Behavioral therapy: operant conditioning (Fordyce); 2 hr/wk, 8 wk (25) (I2) Behavioral therapy, 2 hr/wk, 8 wk, and aerobic exercise, 10–20 min, 5 times/wk, 8 wk (24)	(R1) Aerobic exercise 10–20 min, 5 times/wk, 8 wk (24) (R2) Waiting list control group (23)	Mean scores on McGill Pain Questionnaire, SIP, and depression pretreatment (I1) 20.96, 7.90, 10.40, (I2) 25.54, 8.50, 12.38, (R1) 19.42, 8.42, 11.95 and (R2) 21.17, 6.24, 10.48 and posttreatment (I1) 17.71, 4.72, 8.08, (I2) 12.41, 4.59, 7.31, (R1) 17.52, 5.49, 7.38 and (R2) 20.95, 5.37, 7.03; (I2) significantly more improved than (R1) and (R2); no significant differences after 6 and 12 mo between (I1), (I2), and (R1)
Turner ¹⁵⁰	(I1) Progressive muscle relaxation training (Bernstein & Borkovec) and imagery (24) (I2) Cognitive therapy (Beck) (23) (I3) Cognitive therapy and relaxation training (25)	(R) Waiting list control group (30)	Mean (SD) pain score (VAS) pretreatment vs. posttreatment (I1) 51.29 (21.68) vs. 37.88 (20.07), (I2) 56.91 (18.47) vs. 36.88 (20.45), (I3) 60.68 (22.04) vs. 44.33 (28.45) and (R) 50.07 (21.14) vs. 48.06 (20.97) (I1), (I2), and (I3) significantly more improved than (R); no significant differences between (I1), (I2), and (I3) posttreatment and after 6 and 12 mo on pain, global measure of improvement, or functional status (SIP)
Altmaier ⁴	(I) Standard rehabilitation program and operant conditioning and relaxation training and biofeedback and cognitive behavioral coping skills (24)	(R) Standard inpatient rehabilitation program: physical therapy, aerobic exercises, education, vocational rehabilitation; 3 wk (21)	Mean scores on McGill Pain Questionnaire pretreatment, posttreatment, and after 6 mo (I) 24.24, 23.76, and 22.66 vs. (R) 20.33, 18.05, and 18.19; no significant differences on any outcome measures
Stuckey ¹⁴²	(I) Relaxation training: progressive relaxation, breathing techniques, autogenic training, visual imagery; 8 sessions of 45 min (8)	(R1) EMG biofeedback training; 8 sessions of 45 min (8) (R2) Placebo EMG: no feedback, no relaxation instructions; 8 sessions of 45 min (8)	Mean scores of pain intensity during function test (range 0–100) at first and last treatment session (I) 36.8, 28.0, (R1) 26.2, 31.6, (R2) 42.4, 44.4 and ADL (range 1–7) (I) 2.4, 2.9, (R1) 2.6, 2.5, (R2) 2.2, 2.4. (I) significantly more improved on pain intensity than (R1) and (R2), and significantly more improved on ADL than (R1)
McCauley ¹⁰⁹	(I) Progressive muscle relaxation training (Bernstein & Borkovec) and differential relaxation; 50 min/wk, 8 wk (8)	(R) Self-hypnosis (Barber) and hypnoanalgesic techniques; 50 min/wk, 8 wk (9)	Mean scores on pain (VAS) pretreatment, posttreatment, and after 3 mo (I) 56.9, 39.1, 35.9 vs. (R) 63.1, 43.6, 42.2; no significant differences between groups on pain or depression

Reference	Index Treatment (no. of patients)	Reference Treatment (no. of patients)	Results
Donaldson ³⁶	(I) Progressive relaxation training (Lehrer & Woolfolk), 10 35-min sessions (12)	(R1) Single motor unit biofeedback training (Johnson, Mulder), 10 35-min sessions (12) (R2) Education on anatomy, exercise depression, stress, 10 35-min sessions (12)	Mean scores on McGill Pain Questionnaire (MPQ) and pain intensity (VAS) pretreatment (I) 31.08, 2.51, (R1) 28.75, 2.23, (R2) 34.50, 3.48, posttreatment (I) 27.67, 1.90, (R1) 16.08, 1.26, (R2) 28.58, 2.47 and after 3 mo (I) 32.33, 1.78, (R1) 15.33, 0.72, (R2) 20.08, 0.87; (R1) significantly more improved after 3 mo than (I); no significant differences on pain intensity between groups

ADL = activities of daily living.

Table 25. Details of Randomized Controlled Trials on the Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)/Acupuncture for Chronic Low Back Pain

Reference	TENS/Acupuncture (no. of patients)	Reference Treatment(s) (no. of patients)	Results
TENS			
Deyo ³⁴	(I) TENS 3 times daily 45 min; high frequency (80–100 pulses per sec, amplitude 30) 2 wk plus low frequency (2–4 pulses per sec, amplitude 100) 2 wk or high frequency 4 wk (65)	(R) Placebo TENS 4 wk (60)	Difference (95% CI) between (I) and (R) post-treatment: functional status (SIP) –0.5 (–2.2, 1.3), pain (100 mm VAS) –2.3 (–9.6, 4.9), Schober test (cm) 0.13 (–0.24, 0.50); no significant differences on any of the outcome measures
Marchand ¹⁰³	(I) TENS high frequency (125 μ s pulses, low intensity, 30 min, twice a week, 10 wk) (14)	(R1) Placebo TENS (12) (R2) No treatment (16)	(I) significantly more effective in pain intensity than (R1) after 1 wk, but not after 3 and 6 mo; pain unpleasantness ratings not different; data in graphs
Lehmann ^{90,91}	(I) TENS 250 pulses per sec, 60 Hz, subthreshold intensity, 3 wk (18)	(R1) Placebo TENS (18) (R2) Electroacupuncture 2 times per week, 2–4 Hz, 3 wk (17)	(R2) significantly more relief of peak pain post-treatment and after 6 mo and significantly more relief of average pain posttreatment and after 6 mo than (I) and (R1); no differences between (I) and (R1); data in graphs
Acupuncture			
Coan ²⁸	(I) Acupuncture/electroacupuncture ($\pm$ 10 treatments) (25)	(R) Waiting list control group (25)	Reduction in pain score (11-point scale) and ADL (4-point scale) after 10–15 wk; (I) 51%, 19% vs. (R) 2%, 0%; inadequate treatment in 11 of the 50 patients treated with acupuncture
Mendelson ^{112,113}	(I) Acupuncture 30 min, twice a week, 4 wk (36)	(R) Placebo acupuncture (41)	Reduction in pain score (100 mm VAS) (I) 40% vs. (R) 26% after 4 wk; not significant; cross-over: reduction in pain score (I) now placebo 40% vs. (R) now acupuncture 19%; significant; overall mean percentage decrease in pain score 26.1 for acupuncture and 21.8 for placebo, not significant
MacDonald ⁹⁷	(I) Acupuncture/electroacupuncture 5–20 min, once a week, 7 wk (8)	(R) Placebo acupuncture (9)	Mean percentage reduction posttreatment in pain score and ADL: (I) 57.1, 52.0 vs. (R) 22.7, 5.83. ADL significant
Edelist ³⁸	(I) Manual acupuncture plus electroacupuncture 3–10 Hz, 30 min, 3 treatments (15)	(R) Placebo acupuncture (15)	No. of patients improved posttreatment on pain and spinal mobility (I) 7, 7 vs. (R) 6, 6; not significant
Lehmann ^{90,91}	(I) Electroacupuncture 2 times per week, 2–4 Hz, 3 wk (17)	(R1) Placebo TENS (18) (R2) TENS 250 pulses per sec, 60 Hz, subthreshold intensity, 3 wk (18)	(I) Significantly more relief of peak pain post-treatment and after 6 mo and significantly more relief of average pain posttreatment and after 6 mo than (R2) and (R1); no differences between (R2) and (R1); data in graphs
Gunn ⁵⁵	(I) Rehabilitation program plus acupuncture 1–2 times per week, 10 treatments max (29)	(R) Rehabilitation program (27)	No. of patients with good or total improvement at discharge and after 12 wk in (I) 18, 17 vs. (R) 4, 4; significant

CI = confidence interval; ADL = activities of daily living.